



 COMPUTER-AIDED DRUG DESIGN OF 


















A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF PHARMACY 






I hereby declare that this thesis is my original work and it has been written 
by me in its entirety. I have duly acknowledged all the sources of information 
which have been used in the thesis. 
 













I would like to dedicate this thesis to the two most important people of my 
life my mother and my wife, who have supported me in good and bad times. In 
addition I would like to thank my brother and my friends who have been with me 
throughout the journey.  
 
I wish to express my heartfelt appreciation to my supervisor, Assistant 
Professor YAP Chun Wei, who has provided me with excellent guidance and 
gave enough support and freedom to perform scientific research.  
 
I would like to thank to Dr. CHAI Li Lin, Christina for allowing me to be 
a part of MCL-1 project which gave me valuable experience.  
 
Finally, I wish to thank all members of the Pharmaceutical Data 
Exploration Laboratory (especially Sreemanee) for their suggestions and help in 




Table of Contents 
 
Declaration ..................................................................................................... ii 
Acknowledgements ......................................................................................... iii 
Table of Contents ........................................................................................... iv 
Summary ....................................................................................................... ix 
List of Tables ............................................................................................... xiii 
List of Figures ............................................................................................... xiv 
List of Abbreviations ..................................................................................... xvi 
List of Publications ..................................................................................... xviii 
List of oral and poster presentations .............................................................. xix 
Thesis structure ..............................................................................................xx 
Chapter 1 ........................................................................................................ 1 
Introduction .................................................................................................... 1 
 Drug discovery process ................................................................................1 1.1
 Computer Aided Drug Design .......................................................................3 1.2
 Target identification ................................................................................................... 4 1.2.1
 Homology Modeling .......................................................................................... 4 1.2.1.1
 Lead Discovery ........................................................................................................... 5 1.2.2
 Ligand and Structure based drug design .......................................................6 1.3
 Ligand-based drug design ........................................................................................... 6 1.3.1
 Quantitative structure–activity relationship (QSAR) ......................................... 8 1.3.1.1
 Structure-based drug design ..................................................................................... 10 1.3.2
 Docking ........................................................................................................... 10 1.3.2.1
 Molecular dynamics ......................................................................................... 15 1.3.2.2
 Lead optimization ..................................................................................... 18 1.4
 Objective .................................................................................................. 19 1.5
Chapter 2 ...................................................................................................... 22 
Methods ........................................................................................................ 22 
 QSAR ........................................................................................................ 22 2.1
 Data selection and curation ....................................................................................... 25 2.1.1
 Descriptor calculation ............................................................................................... 25 2.1.2
 Descriptor selection .................................................................................................. 26 2.1.3
v 
 
 Pre-processing.................................................................................................. 26 2.1.3.1
 Selection .......................................................................................................... 27 2.1.3.2
2.1.3.2.1 Genetic Algorithm ...................................................................................... 28 
 Model development .................................................................................................. 29 2.1.4
 k nearest neighbor ............................................................................................ 30 2.1.4.1
 Support Vector Machine .................................................................................. 31 2.1.4.2
 Applicability domain (AD) .............................................................................. 31 2.1.4.3
 Validation ................................................................................................................. 33 2.1.5
 Internal validation ............................................................................................ 34 2.1.5.1
 External validation ........................................................................................... 34 2.1.5.2
 Predictive performance .................................................................................... 35 2.1.5.3
 Consensus model ...................................................................................................... 37 2.1.6
 Docking ..................................................................................................... 38 2.2
 Receptor Preparation ................................................................................................ 38 2.2.1
 Identification of active site ....................................................................................... 38 2.2.2
 Ligand preparation .................................................................................................... 39 2.2.3
 Docking .................................................................................................................... 39 2.2.4
 Molecular Dynamics .................................................................................. 39 2.3
 System Preparation ................................................................................................... 40 2.3.1
 Minimization ............................................................................................................ 40 2.3.2
 Heating up the system and equilibration .................................................................. 41 2.3.3
 Production run .......................................................................................................... 41 2.3.4
Chapter 3 ...................................................................................................... 42 
Neuraminidase .............................................................................................. 42 
 Influenza virus ........................................................................................... 42 3.1
 Influenza A ............................................................................................................... 43 3.1.1
 Structure of Influenza A virus .................................................................................. 43 3.1.2
 Virus life cycle ......................................................................................................... 44 3.1.3
 Antigenic variation ................................................................................................... 47 3.1.4
 Antigenic Drift ................................................................................................. 47 3.1.4.1
 Antigenic Shift ......................................................................................................... 48 3.1.5
 Characteristic function of Neuraminidase ................................................................ 48 3.1.6
 Neuraminidase as a drug target ................................................................................ 51 3.1.7
 Structure of neuraminidase ....................................................................................... 51 3.1.8
 Active site of neuraminidase .................................................................................... 52 3.1.9
 Neuraminidase inhibitors ..................................................................................... 54 3.1.10
 Drug resistance ..................................................................................................... 55 3.1.11
Chapter 4 ...................................................................................................... 57 
Neuraminidase Methods ................................................................................ 57 
 QSAR ........................................................................................................ 57 4.1
 Dataset curation ........................................................................................................ 57 4.1.1
vi 
 
 Descriptor calculation ............................................................................................... 59 4.1.2
 Development of QSAR model and screening ........................................................... 60 4.1.3
 Docking ..................................................................................................... 60 4.2
 Structure preparation ................................................................................................ 60 4.2.1
 Active site ................................................................................................................. 62 4.2.2
 Dataset for virtual screening ..................................................................................... 62 4.2.3
 Molecular docking .................................................................................................... 62 4.2.4
 Energy minimization and rescoring .......................................................................... 63 4.2.5
Chapter 5 ...................................................................................................... 66 
Neuraminidase Results and Discussion ......................................................... 66 
 QSAR ........................................................................................................ 66 5.1
 Base Models ............................................................................................................. 69 5.1.1
 Performance of consensus model ............................................................................. 69 5.1.2
 Compounds outside AD ........................................................................................... 70 5.1.3
 Docking ..................................................................................................... 75 5.2
 Energy Minimization and Rescoring ........................................................................ 80 5.2.1
 Standard Deviation of the docking scores........................................................ 80 5.2.1.1
 Correlation between IC50 and average binding free energy (ABFE) .............. 82 5.2.1.2
 Conformations of Glutamic276 in non-mutant strains ............................................. 84 5.2.2
 Conformation of Glutamic276 leading to resistance ................................................ 84 5.2.3
 N294S and H274Y mutations .......................................................................... 84 5.2.3.1
 R292K mutation............................................................................................... 87 5.2.3.2
 Comparison of the poses of potential inhibitors with wild strains ............................ 88 5.2.4
 Comparison of the poses of potential inhibitors with mutant strains ........................ 91 5.2.5
Chapter 6 ...................................................................................................... 97 
MCL-1 .......................................................................................................... 97 
 Apoptosis .................................................................................................. 97 6.1
 Apoptosis and Cancer ............................................................................................... 98 6.1.1
 Apoptotic Pathways .................................................................................................. 98 6.1.2
 BCL-2 Protein Family ............................................................................... 101 6.2
 BCL-2 family protein-protein interactions ............................................................. 102 6.2.1
 BCL-2 family proteins as therapeutic targets ......................................................... 102 6.2.2
 BH3 mimetic as potential drugs ............................................................................. 104 6.2.3
 MCL-1 as a drug target ........................................................................................... 105 6.2.4
 MCL-1 ..................................................................................................... 106 6.3
 MCL-1 function ...................................................................................................... 108 6.3.1
 MCL-1 versus BCL-2 family member’s specificity ............................................... 108 6.3.2
 BH3 and interaction with MCL-1 ........................................................................... 109 6.3.3
 Position 2d ..................................................................................................... 110 6.3.3.1
 Position 3a ..................................................................................................... 111 6.3.3.2
vii 
 
 Positions 3d .................................................................................................... 111 6.3.3.3
 Position 4a ..................................................................................................... 111 6.3.3.4
 Positions 3g .................................................................................................... 112 6.3.3.5
 Targeting MCL-1.................................................................................................... 112 6.3.4
 ABT-737 ........................................................................................................ 113 6.3.4.1
Chapter 7 .................................................................................................... 114 
MCL-1 Methods .......................................................................................... 114 
 Docking ................................................................................................... 114 7.1
 Structure preparation .............................................................................................. 114 7.1.1
 Active site ............................................................................................................... 115 7.1.2
 Dataset for docking ................................................................................................. 115 7.1.3
 Fluorescence polarization assay ..................................................................... 116 7.1.3.1
 Molecular Docking ................................................................................................. 118 7.1.4
 Molecular Dynamics ................................................................................ 118 7.2
 System preparation ................................................................................................. 118 7.2.1
 Minimization, heating up and equilibration of system ........................................... 119 7.2.2
 Production run ........................................................................................................ 120 7.2.3
 Binding free energy ................................................................................................ 121 7.2.4
Chapter 8 .................................................................................................... 123 
MCL-1 Results and Discussion .................................................................... 123 
 MCL-1 versus BCL-XL ............................................................................... 123 8.1
 Docking ................................................................................................... 123 8.2
 Molecular Dynamics ................................................................................ 124 8.3
 Clustering ............................................................................................................... 124 8.3.1
 Binding free energy calculation .............................................................................. 127 8.3.2
 Interactions ............................................................................................................. 127 8.3.3
 ST_1_046 ....................................................................................................... 127 8.3.3.1
 ST_1_109 ....................................................................................................... 128 8.3.3.2
 ST_1_R1N ..................................................................................................... 128 8.3.3.3
 ST_1_208 ....................................................................................................... 131 8.3.3.4
 ST_1_247 ....................................................................................................... 131 8.3.3.5
 ST_1_202 ....................................................................................................... 131 8.3.3.6
 ST_1_159 ....................................................................................................... 132 8.3.3.7
 ST_1_249 ....................................................................................................... 132 8.3.3.8
 ST_1_162 ....................................................................................................... 132 8.3.3.9
 ST_1_227 and ST_1_222 .............................................................................. 134 8.3.3.10
 ST_1_261 ....................................................................................................... 134 8.3.3.11
 Conformation of the residues ................................................................................. 134 8.3.4
 Comparison between different scaffolds ................................................................ 135 8.3.5
 Rhodanine ...................................................................................................... 135 8.3.5.1
 Thiohydantoin ................................................................................................ 136 8.3.5.2
viii 
 
 Hydantoin ...................................................................................................... 137 8.3.5.3
 Thiazolidinedione .......................................................................................... 137 8.3.5.4
Chapter 9 .................................................................................................... 138 
Conclusions ................................................................................................ 138 
 Contributions .......................................................................................... 138 9.1
 Limitations .............................................................................................. 144 9.2
 Future work ............................................................................................ 145 9.3






Drug discovery is a lengthy and complicated process. In order to reduce 
the time to market, computational methods such as molecular modeling, 
chemoinformatics and chemometrics have been incorporated successfully in many 
drug discovery projects. The aim of the study is to contribute to the achievement 
of Pharmaceutical Data Exploration Laboratory in the field of drug discovery by 
developing novel drugs against two targets i.e. neuraminidase and MCL-1 and in 
process learn different methodologies used in computer aided drug design such as 
QSAR, docking and molecular dynamics. The two targets were selected due to the 
difference in the nature of the proteins. While neuraminidase has small buried 
hydrophobic pocket, MCL-1 has long narrow binding site on the surface of the 
protein. The difference in the active site has its own challenges and can lead to 
different approaches in computer aided drug design.  
Influenza is a contagious viral disease of respiratory tract. The primary 
drug target for treatment influenza is neuraminidase due to its conserved nature 
and important role in virus life cycle. Neuraminidase can be divided into two 
groups i.e. group I and group II. Oseltamivir and zanamivir are two FDA 
approved drugs for treatment of influenza. Mutations like H274Y, N294S and 
R292K have already resulted in resistance against oseltamivir and zanamivir.  
These mutations are group specific e.g. H274Y and N294S belong to group I 
while R292K is found in group II neuraminidase. Hence, pan neuraminidase 




To achieve this, consensus QSAR model with applicability domain was 
developed to screen potential neuraminidase inhibitors. The compounds screened 
by model were later used in docking study against group I and group II 
neuraminidase strains along with major mutations i.e. H274Y, N294S and R292K 
to discover novel pan neuraminidase inhibitors.  
The results show that the probable inhibitors had similar orientations as 
zanamivir and oseltamivir in wild type i.e.N1_closed and N9_closed. As a result 
of H274Y, the side chain was found to be pushed back thus negating the inward 
movement of Glu276. The longer side chain was found to be facing away from 
Glu276 and closer to Ile222, Arg224, Ala246 (N1)/Ser246 (N9). R292K mutation 
resulted in the constriction of the hydrophobic cavity thereby resulting in rotation 
of side chain. ZN88 was able to form hydrogen bond between amino group of the 
side chain and Glu276, Glu277, Asp151 in both wild and mutant strains. The 
extra flexibility of the side chain in ZN88, ZN33 and ZN35 was due to bifurcation 
at 1st atom. Thus, it can be concluded that inhibitors having guanidino group, 
flexible side chain with an amino group can be pan neuraminidase inhibitors. Low 
SD observed for of ZN43, ZN88, ZN35 and ZN46 indicates less deviation in in 
binding against mutant strains as well as different groups of neuraminidase.  
 Anti-apoptotic proteins, like BCL-XL, play important roles in apoptosis 
and have been a target of number of anti-cancer efforts. However, MCL-1 
overexpression has been one of the reasons behind the resistance against anti-
cancer drugs targeting BCL-XL. In a recent study rhodanine based compounds 
have shown promise as MCL-1 specific inhibitor. However, compounds with 
xi 
 
rhodanine scaffold are known as pan assay interference compounds (PAINS). 
Hence, the second objective is to analyze the role of rhodanine scaffold in 
selective inhibition of MCL-1 to guide the development of more potent and 
selective MCL-1 inhibitors. In order to achieve second objective, our collaborator 
Miss Tang Shi Qing graduate student Dr. Christina CHAI synthesized compounds 
belonging to four different classes i.e. rhodanine, thiazolidinedione, thiohydantoin 
and hydantoin by scaffold hoping. 
Molecular dynamics was performed to analyze the interactions of MCL-1 
with compounds of different scaffolds in order to improve potency and selectivity 
of MCL-1 inhibitors. Crystal structure of MCL-1 inhibitors reported in previous 
studies utilizes mostly one or sometimes two pockets in MCL-1 binding grove. 
On the other hand, most active compound ST_1_046, belonging to rhodanine 
scaffold, was found to be aligned with the hydrophobic grove and interacted with 
pockets P1, P2 and P3. This alignment was supported by non-polar rhodanine ring 
flanked with electronegative groups. More polar central ring of other scaffolds led 
to decrease in activity. Thus it was concluded that increase in occupancy of the 
binding grove, which depends on the electrostatics of ligand, increases the 
activity. 
On the basis of the computational results, five compounds with rhodanine 
scaffold were synthesized by our collaborators. Analysis of these compounds 
indicates that further increase in length of the inhibitor does not lead to better 
activity. Thus in future, compounds with bulkier non-polar central group can be 
developed which can help to improve the activity to a greater extent. 
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Both studies have been successful in predicting the probable inhibitors for 
neuraminidase and MCL-1. Predicted probable neuraminidase inhibitors will be 
subjected to molecular dynamics study against different mutant strains. ZN43, 
ZN88, ZN35 and ZN46 will be used to develop pharmacophore model for 
screening potent pan neuraminidase inhibitors. Recent discovered neuraminidase 
10 and 11 will be included for the screening and testing. The effect of the 
compounds on the human sialidase also needs to be tested in the future.  
The knowledge gained from the interaction of the ligands with MCL-1 
will be utilized to develop novel selective inhibitors against MCL-1. In-vitro 
studies will be performed against both MCl-1 and BCL-2 to establish the 
selectivity of the ligands. As poor results were obtained in docking studies 
therefore novel algorithms should be developed to target such binding grooves. 
Despite the fact that molecular dynamics improved the results, there is a need to 
establish a relation between number and duration of trajectories required for a 
molecular dynamics experiment to attain a good correlation between predicted 
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Thesis structure can be divided into four main sections i.e. introduction, 
methods, neuraminidase and MCL-1. The first section describes the application 
and importance of CADD in drug discovery process. The components of CADD, 
especially those applied in our work, are described in chapter 1.  The second 
chapter describes the methods used to achieve our objectives i.e. QSAR, docking 
and molecular dynamics. The parameters specific to any particular study is 
described in their respective sections.  
The third and fourth sections are divided into three chapters each i.e. 
introduction, methods, results and discussion. Chapter 3 describes influenza and 
its life cycle. It also elaborates neuraminidase and its role in the influenza life 
cycle, thereby making it an appropriate target for influenza inhibition.  
The methods used in discovery of neuraminidase inhibitors and 
parameters specific to it are described in chapter 4. The development of QSAR 
model and its application to screen ZINC library (J. J. Irwin & Shoichet, 2005; 
John J. Irwin, Sterling, Mysinger, Bolstad, & Coleman, 2012) along with docking 
study is explained in this chapter. 
Chapter 5 consists of the results and discussion for neuraminidase section. 
It describes the prediction performance of QSAR, compounds outside the AD of 
the model and screening of the ZINC library. In addition, the compounds selected 
as result of docking, their poses in wild and mutant strains are discussed.   
xxi 
 
The role of apoptosis and its control by BCL-2 protein family is described 
in chapter 6. This chapter also explains the different role of apoptotic and anti-
apoptotic proteins. In addition, the importance of MCL-1 as a drug target is also 
discussed. 
The application of molecular dynamics to predict the poses and understand 
the dynamics of MCL-1 is described in chapter 7. The use of multiple trajectories 
to increase the accuracy is also shown. This chapter also highlights the limitation 
of docking in predicting the accurate pose. 
The orientation of compounds predicted by 25ns and 45ns trajectory 
resulting in MCL-1 inhibition is discussed in chapter 8. This chapter describes the 
importance of P2 pocket in interaction with ligand. Moreover, the role of 
electrostatics and scaffold of compounds in determining the activity is discussed. 
The last chapter i.e. chapter 9 describes the contributions of the two 
projects involved in this work and also the limitations and future work.






Computer aided drug design (CADD) is emerging as an important 
component of drug discovery process as it helps to reduce time to market and cost 
of the drugs. Traditionally CADD includes ligand-based drug design i.e. 
quantitative structure activity relationship (QSAR) and structure based drug 
design i.e. docking. Recently, molecular dynamics emerged as a vital part of the 
drug discovery process. The first section of this chapter (1.1) describes overview 
of drug discovery process and application of CADD. The objective and thesis 
structure are described in 1.5, 1.6 sections respectively. 
 
 Drug discovery process 1.1
 
Drug discovery and development is time-consuming, costly process and 
risky endeavor. It takes about 15 years and $1- $1.5 billion to turn a promising 
lead compound into a potential drug. Despite the increase in investment in drug 
discovery, the output is considerably low, mainly due to high rate of drug failure 
in clinical trials (Allison, 2012). Consequently, in order to reduce the cost and 
time of a drug to reach market, new technologies were ventured.   
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With the advancement in areas of genomic and proteomics and 
development of high-throughput screening (HTS) (Broach & Thorner, 1996; 
Hertzberg & Pope, 2000), the requirement of new lead compounds was felt. 
Combinatorial chemistry which can create large population of structurally 
different compounds became an attractive choice (W. A. Warr, 1997). As 
combinatorial chemistry grew and was adapted in many research studies, the need 
for a faster method to screen compounds arise. To cope with these challenges, 
both experimental and theoretical methods were developed. HTS, for instance, 
involves screening large libraries of chemicals against a biological target while 
virtual screening screens large libraries of chemicals computationally and then 
verifying the predicted compounds  in vitro/in vivo (Shoichet, 2004). The purpose 
of HTS is to speed up the drug discovery process by screening large compound 
libraries. HTS involves target identification, reagent preparation, compound 
management, assay development and high-throughput screening which requires 
great care (Martis E A, 2011) Due to individual biochemical assays with over 
millions of compounds huge cost and time consumed with HTS (Subramaniam, 
Mehrotra, & Gupta, 2008). This has led to more faster and effective 
computational approach i.e. computational virtual screening or virtual screening. 
In comparison to HTS, virtual screening requires structural information either of 
ligands (ligand-based virtual screening) or of the target itself (target-based virtual 
screening) (Ekins, Mestres, & Testa, 2007). Though both virtual screening and 
HTS are complementary process (Bajorath, 2002), virtual screening gives much 
higher hit rate (Yun Tang, Weiliang Zhu, Kaixian Chen, & Hualiang Jiang, 2006).  
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The rapid growth of low-cost computational power in last decades has 
increased the application of computational technology in the drug discovery 
pipeline and is known as CADD. CADD is a broad term including different 
computational tools involved in database, screening potential lead molecules, 
analyzing the cause of effectiveness or ineffectiveness of a particular drug, 
modeling and simulation of the compound or biomolecules (Dalkas, Vlachakis, 
Tsagkrasoulis, Kastania, & Kossida, 2013; Ooms, 2000).  
 Computer Aided Drug Design  1.2
 
The general steps of drug discovery can be defined (Figure1.1) as disease 
related genomic, target identification, target validation, lead discovery, lead 
optimization, preclinical trials and clinical trials (Y. Tang, W. Zhu, K. Chen, & H. 
Jiang, 2006). Application of computational tools is rapidly gaining 
implementation in drug discovery and is generally known as CADD 
(Kapetanovic, 2008). Initially, CADD tools were developed for lead optimization 
but now they find application in almost all phases of drug discovery (Y. Tang et 
al., 2006). CADD mainly involves in 1) identification and optimization of new 
drugs using chemical and biological information of the ligands and structures. 2) 
filtration compounds with undesirable properties and select most promising 
compounds (Kapetanovic, 2008; Ou-Yang et al., 2012; Rahman et al., 2012; C. 
M. Song, Lim, & Tong, 2009).    
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 Target identification 1.2.1
 
The two main reasons for drug failure are lack of activity against proposed 
target or its unsafe nature. Hence, target identification and validation is the first 
and most important stage of any drug discovery process (Hughes, Rees, 
Kalindjian, & Philpott, 2011). Ideal novel drug targets should be a part of a 
crucial biological pathway, different from previously known targets, functionally 
and structurally characterized; and druggable i.e. can bind to small molecules 
(Bakheet & Doig, 2009).  Structure based computational methods have shown 
promise in predicting targets such as in case of protein kinase inhibitors (Rockey 
& Elcock, 2006). Potential drug targets have also been identified using inverse 
docking i.e. docking a compound with a known biological activity against 
different receptors (Y. Z. Chen & Zhi, 2001) and screening target libraries 
(Rognan, 2006).  
 Homology Modeling 1.2.1.1
 
In absence of experimental structures such as in case of most membrane 
proteins, homology modeling is used to predict target structure (Cavasotto & 
Phatak, 2009; Kopp & Schwede, 2004; Elmar Krieger, Nabuurs, & Vriend, 2005). 
Homology modeling takes advantage of the fact that protein structure is more 
conserved than sequence and similar sequence have similar structure. Homology 
modeling is a multistep process (Figure1.2) and can be summarized into 
following steps (Elmar Krieger et al., 2005): 
1. Template recognition and initial alignment 
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2. Alignment correction 
3. Backbone generation 
4. Loop modeling, Side-chain modeling 
5. Model optimization 
6. Model validation 
Homology works best with sequence identity of more than 40% between 
the initial sequence and the homologous templates. The accuracy drops 
considerably as sequence identity drops below 30% (Marti-Renom et al., 2000). 
Besides dedicated software like Modeller (https://salilab.org/modeller/) (Eswar et 
al., 2007) and multi-utility software Yasara (http://www.yasara.org/) (E. Krieger 
et al., 2009) webservers like SWISS-MODEL (http://swissmodel.expasy.org/) 
(Biasini et al., 2014), are frequently used to predict protein structure. Homology 
modeling has been utilized in several studies such as in deduction of bovine μ- 
calpain inhibitor-binding domains (Chai, Lim, Lee, Chai, & Jung, 2014), human 
muscarinic acetylcholine receptors (T. Thomas et al., 2014), G-protein-coupled 
receptors (Yarnitzky, Levit, & Niv, 2010) and Human Kynurenine 
Aminotransferase III (Nematollahi, Church, Nadvi, Gorrell, & Sun, 2014) being 
some of the recent examples. 
 Lead Discovery 1.2.2
 
Once we have a defined target, next step is to find a lead molecule. A lead 
molecule has at least weak affinity and minimum toxic effects and forms the 
starting point of the drug like compound (Verlinde & Hol, 1994). Lead structures 
CHAPTER 1: INTRODUCTION                                                                          6 
 
 
should possess following properties: (1) simple chemical features so that they can 
be easily optimized; (2) have an established structure activity relationship; (3) 
novel in order to get patent; and (4) good absorption, distribution, metabolism and 
excretion (ADME) properties (Oprea, Davis, Teague, & Leeson, 2001). Based on 
the presence or absence of the target structure, lead discovery can be divided into 
two major class i.e. ligand-based lead discovery and structure-based lead 
discovery. 
 Ligand and Structure based drug design 1.3
 
Depending on availability of structural information of the target, CADD 
can be divided into two categories (Figure1.3) i.e. ligand-based and structure-
based CADD. Structure-based CADD relies on the knowledge of the target 
protein structure to predict potential inhibitors and their binding poses. On the 
other hand, ligand-based approach utilizes the knowledge of active and inactive 
compounds to construct quantitative structure-activity relation (QSAR) models 
for predicting possible ligands (Kalyaanamoorthy & Chen, 2011). Both structure 
and ligand-based approaches find application in lead discovery as well as lead 
optimization. 
  Ligand-based drug design 1.3.1
 
Ligand-based CADD uses a set of structurally diverse compounds with 
known activity for a particular target and is based on the hypothesis that compou- 




Figure1.1 Drug Discovery Pipeline 
 
Figure1.2 Workflow of homology modeling 
 
Figure1.3 Computer aided drug design   
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-nds with similar structure have similar properties.  Based on the presence of 
either active and/or inactive compounds, ligand-based lead discovery can be 
divided into two groups (1) selection of compounds based on chemical similarity 
or (2) the construction of a QSAR model to predict probable lead like compounds. 
 Quantitative structure–activity relationship (QSAR)  1.3.1.1
 
QSAR is used often in drug discovery projects to find new lead 
compounds and works by establishing mathematical relation between structure 
and function using chemometric method (Kubinyi, 1997; S. Zhang, 2011).  
In drug discovery, structure implies physicochemical properties of the 
compounds; function refers to biological activity and chemometric method 
includes multiple linear regression (MLR), support vector machine (SVM), 
artificial neural network (ANN) etc. Since the pioneer work of Hansch and Free-
Wilson, a lot of progress has been made in QSAR with the rise of 3D (Verma, 
Khedkar, & Coutinho, 2010) and even 4D QSAR (Andrade, Pasqualoto, Ferreira, 
& Hopfinger, 2010). 
A QSAR model has following objectives: 
1. To identify chemical properties responsible for biological activity. 
2. To optimize the existing leads in order to improve their biological 
activities. 
3. To predict the biological activities of novel compounds. 
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A QSAR workflow consists of creating a combined dataset of active and 
inactive compounds, calculating descriptors of the compounds present in dataset, 
splitting dataset into modeling and validation set, creating QSAR model using 
modeling set and evaluating it by the validation set. The model is used to screen a 
desired chemical library and accuracy of the screening is judged from the 
validation results performed earlier. Success of QSAR model not only depends on 
the dataset but also on the descriptors and methods used for modeling. As 
effective screening depends on the dataset used for training the model, a diverse 
dataset can increase the chemical space of the model (Kubinyi, 1997; S. Zhang, 
2011).  
In addition to the extensive use in predicting the bioactivity, QSAR has 
also been applied to distinguish drug-like from non-drug-like molecules, explain 
possible molecular mechanism of the receptor-ligand interactions (G. F. Yang & 
Huang, 2006). prediction of physicochemical, pharmacokinetic (Xu et al., 2007), 
and ADMET properties (Klopman, Stefan, & Saiakhov, 2002; Winkler, 2002). 
Some of the recent application of QSAR in drug discovery are discovery novel 
GPCR ligands (A. Tropsha & Wang, 2006), inhibitors of acetylcholinesterase in 
Alzheimer's disease (K. Y. Wong, Duchowicz, Mercader, & Castro, 2012), HIV 
inhibitors (Debnath, 2005), neuraminidase inhibitors (N. Sharma & Yap, 2012; 
Zheng et al., 2006) etc. 
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  Structure-based drug design 1.3.2
 
Unlike ligand-based lead discovery, structure based approach requires 
protein structure and exploits the protein-ligand interactions to select compounds 
that bind strongly to the biologically relevant target (Ghosh, Nie, An, & Huang, 
2006). In the scenario with no information on the compounds active against the 
target, de novo design approach can be used to identify possible leads (Arakawa, 
Hasegawa, & Funatsu, 2007). However, de novo design is not restricted to a 
certain condition and can be used whenever a novel lead molecule is required 
such as in the identification of D816V mutant-selective c-KIT inhibitors (H. Park, 
Lee, Lee, & Hong, 2014), Aurora A kinase inhibitors (Rodrigues et al., 2013), 
novel HCV helicase inhibitor (Kandil et al., 2009), and  inhibitors of cyclophilin 
A (Ni et al., 2009), among many others. Structure-based drug design has been 
successfully applied in many drug discovery projects such as design of GPCR 
inhibitors (Congreve, Dias, & Marshall, 2014), catechol-O-methyltransferase 
inhibitors (Ma, Liu, & Wu, 2014), carbonic anhydrase inhibitors (Guzel, 
Innocenti, Vullo, Scozzafava, & Supuran, 2010), angiotensin-I converting enzyme 
inhibitors (Anthony, Masuyer, Sturrock, & Acharya, 2012) etc. 
 Docking 1.3.2.1
 
Docking program aims to predict the orientation and conformation of the 
ligand within the binding site of a receptor. This is achieved by sampling the 
conformational space of ligand and binding site which are later used to find the 
binding interactions between ligand and protein. This gives us a score also known 
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as binding score. The compounds and their respective poses are ranked on the 
basis of binding score. By this way, docking can predict strength of the interaction 
of possible lead like molecule prior to its synthesis and in vitro or in vivo 
evaluation.  
Docking can be divided into of two main steps. In the first step, the 
algorithm tries to predict the possible binding modes for protein-ligand pair. The 
aim of the scoring function selected for this step is to roughly distinguish the true 
binding poses without compromising on speed. The second step involves 
selection of several poses from the first stage and revaluating them. The scoring 
function used in this step is generally more complex and attempts to estimate 
binding energies as accurately as possible. 
Scoring functions are mathematical equations to calculate binding affinity 
of a ligand towards a receptor. Any protein-ligand interaction can be defined by 
the equation 1. 
                                              ΔGbind 
[P]aq + [L]aq           ⇌        [P+L]aq  (1) 
The free energy of binding i.e. ΔG is obtained with the Gibbs-Helmholtz 
equation:  
ΔG = ΔH - TΔS   (2) 
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Where ΔH is the enthalpy, T is the temperature in Kelvin and ΔS the entropy. The 
binding constant i.e. Ki can be related with ΔG by following equation: 
        ΔG = -RT1nKi        (3)  
 Evaluation and ranking of predicted poses is an important aspect of any 
docking process.  An ideal scoring function should be able to identify true binding 
poses. An ideal scoring function will be computationally too expensive making 
them unsuitable for large number of protein-ligand interactions. Therefore every 
docking program makes its own set of approximations and do not fully account 
for a number of physical phenomena for example, entropic effects, leading to 
difference in the results between them (Kitchen, Decornez, Furr, & Bajorath, 
2004; Mohan, Gibbs, Cummings, Jaeger, & DesJarlais, 2005). Moreover 
exhaustiveness of the scoring function can depend on the stage of docking as a 
less exhaustive scoring scheme is used in pose selection process but more 
complex scoring scheme is used while estimating binding energies of the selected 
poses. 
Broadly scoring functions can be classified in three different types i.e. 
force-field based, knowledge based and empirical based scoring functions. The 
parameters of force field scoring functions such as DOCK (Ewing, Makino, 
Skillman, & Kuntz, 2001), GOLD (Jones, Willett, Glen, Leach, & Taylor, 1997) 
are derived from both experimental data and ab initio quantum mechanical 
calculations. However, a major hurdle lies in the treatment of solvent in ligand 
binding (Huang, Grinter, & Zou, 2010) . Empirical scoring functions like FlexX 
(Matthias Rarey, Bernd Kramer, Thomas Lengauer, & Gerhard Klebe, 1996) 
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estimate the binding affinity of a complex on the basis of a set of weighted energy 
term. The coefficients are obtained from experimentally determined binding 
energies and X-ray structural information. Compared to the force field scoring 
functions, the empirical scoring functions are much faster. On the other hand, 
dependence on the molecular data sets often yields different weighting factors for 
the various terms. Hence, terms from differently fitted scoring functions cannot 
easily be recombined into a new scoring function (Kitchen et al., 2004). 
Knowledge based scoring functions rely on the information derived from the 
experimental structures. In comparison to the other two scoring functions, 
knowledge-based scoring functions have a good balance between accuracy and 
speed (S. Y. Huang et al., 2010). However, lack of experimental structures can 
lead to problems (Kitchen et al., 2004). Consensus scoring such as CScore has 
been utilized to overcome the weakness of individual scoring functions. SYBYL’s 
CScore uses DOCK-like D-Score and GOLD-like G-score which are force field 
based scoring functions, ChemScore (Eldridge, Murray, Auton, Paolini, & Mee, 
1997) an empirical based function and Potential of Mean Force (PMF) (Muegge, 
2002) which is knowledge based scoring function. 
Despite many attempts to make prediction as accurate as possible, docking 
methods are still far from being perfect. There are many factors leading to 
inaccuracy of the docking predictions. The lack of a fast and accurate scoring 
function is perhaps the most limiting factor (Sousa, Fernandes, & Ramos, 2006). 
Lack of protein flexibility is another reason for inaccurate predictions by docking. 
During protein-ligand interaction, protein changes its conformation to achieve 
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best possible pose of the ligand in a phenomenon known as induced fit. To 
include the effect of induced fit, flexibility of the protein must be considered. 
However, including the degrees of freedom (DOF) of a receptor will make 
docking an even more challenging task. Hence, most docking programs consider 
ligand as flexible while keeping receptor rigid (Zoete, Grosdidier, & Michielin, 
2009). Implicit protein flexibility is achieved in SYBYL by application of soft 
docking algorithms which work by using a relaxed representation of the 
molecular surface. 
Every year, a number of successful applications of docking are published 
in literature. Docking has played pivotal role in many drug discovery projects 
such as development of dipeptidyl peptidase IV (Tanwar, Tanwar, 
Shaquiquzzaman, Alam, & Akhter, 2014), Sortase A (Uddin & Saeed, 2014), 
Poly (ADP-ribose) polymerase-1 (Hannigan et al., 2013), HIV protease 
(Wlodawer & Vondrasek, 1998), neuraminidase (Shan, Ma, Wang, & Dong, 
2012), monoamine oxidase (Ferino, Vilar, Matos, Uriarte, & Cadoni, 2012) 
inhibitors as well as drug molecules against protein kinases and phosphatases (C. 
F. Wong & Bairy, 2013), potassium ion channels (Dave & Lahiry, 2012),  solute 
carrier transporters (Schlessinger, Khuri, Giacomini, & Sali, 2013) etc. 
There are many docking programs that differ in sampling algorithms, the 
handling of ligand and protein flexibility, and scoring functions (Lyne, 2002). 
Some of them are mentioned in Table1.1. 




Table1.1 Brief overview of some of the common docking software 
 
Software Algorithm Scoring function Success Stories 





Force field or 
contact score 
(Mohan Sahoo, 
Chandra Dinda, Ravi 
Kumar, Panda, & S 
Brahmkshatriya, 2014) 
AutoDock (Morris et 
al., 1998) 
Lamarckian 
GA Force field 
(Khalid & Paul, 2014; 
Tan, Khairuddean, 
Wong, Khaw, & 
Vikneswaran, 2014) 
FlexX (M. Rarey, B. 
Kramer, T. Lengauer, 
& G. Klebe, 1996) 
Incremental 
construction Empirical score 
(Saeed, Khan, Rafique, 
Shahid, & Iqbal, 2014) 
GOLD (Jones, 
Willett, & Glen, 
1995) 
GA Empirical score (Grover et al., 2014) 




e Carlo (MC) 







Gaussian score or 
empirical scores (Korošec et al., 2014) 
ICM (Abagyan, 
Totrov, & Kuznetsov, 
1994) 






(Abdellatif, Belal, & 
Omar, 2013; Allen et 
al., 2013) 
SYBYL (SYBYL-X) Incremental construction Consensus score 
(Dutta Gupta et al., 
2014; Jayanthi et al., 
2014) 
 
 Molecular dynamics 1.3.2.2
 
Though studies based on crystal structure played a major role in drug 
discovery projects, the static nature of the proteins have led drug designers to look 
for computational techniques, such as molecular dynamics, to study systems more 
dynamically (Durrant & McCammon, 2011). Molecular dynamics simulations, 
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developed in the late 1970s, is based on Newtonian physics and the general 
workflow can be described in the following steps (Durrant & McCammon, 2011; 
H.-J. Huang et al., 2010) 1) the determination of initial positions and velocities of 
every atom; 2) the calculation of forces applied on the investigated atom using 
inter-atomic potentials; 3) move the atoms to the position defined by forces 
calculated in step 2; 4) simulate for a short time period and move to step 2.  
Classical molecular dynamics is based on Newton’s laws of motion (eq 1) 
which are integrated in time dependent manner.  
an =  fn/m   (1) 
from time n to n+1the velocity and coordinates changes according to following : 
vn+1 = vn + anΔt 
xn+1 = xn + vnΔt + ½ (anΔt2) 
where v is velocity, x is atomic coordinate and Δt is magnitude of the integration 
time step.  
These steps are repeated for long duration resulting in the trajectory of the atomic 
motions during that period (Beck & Daggett, 2004). 
Force field refers to a mathematical formula and associated parameters 
that describes the potential energy of the protein as a function of its atomic 
coordinates. AMBER, CHARMM, GROMOS and OPLS-AA are the most 
commonly used force fields. The force fields are associated with molecular 
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dynamics suites and thus the choice of force field is a secondary one. There is no 
consensus which force field is better and often simulations performed with same 
parameters on different force fields generate consistent results (Hug, 2013; Price 
& Brooks, 2002).  
Molecular dynamics is generally considered as the simulation of all atoms 
present in the system. This is called as full atomistic simulation. Despite the 
increase in computational power and use of Graphics Processor Unit (GPU) in 
molecular dynamics, a full atomistic simulation for longer durations is a daunting 
task. Hence, different variants of classical molecular dynamics has been designed 
such as temperature accelerated molecular dynamics, replica exchange molecular 
dynamics, steered molecular dynamics, coarse grained molecular dynamics etc. 
(Hug, 2013; Kerrigan, 2013). 
MD simulation has two broad applications. First is to analyze the actual 
dynamics of the system thereby observing the motion of biomolecules at the 
atomic scale for example, folding/unfolding of peptides or small proteins. The 
second application is to derive equilibrium and kinetic properties of the system 
and compare them with experiments to interpret the molecular mechanisms 
behind a particular biological activity (X. Cheng & Ivanov, 2012). 
 Some of the recent studies involving molecular dynamics are defining 
binding mode of phosphoinositide 3-kinase α-selective inhibitor (Bian et al., 
2014), analysis of the active site of enzyme mannosyltransferase in Leishmania 
major (Shinde, Mol, Jamdar, & Singh, 2014), analysis of interaction of the 
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inhibitors against adipocyte fatty-acid binding protein  (J. Chen, Wang, & Zhu, 
2014), discovery of Hsp90 inhibitors (Li et al., 2014), analysis of CDK2 inhibitors 
(Tripathi & Singh, 2014) etc.  
 Lead optimization 1.4
 
Advances in combinatorial chemistry and HTS have resulted in 
tremendous increase in number of lead molecules (Chaturvedi, Decker, & 
Odinecs, 2001). This has made lead optimization a much required step which 
aims to identify compounds with increased likelihood of success in clinical trials 
(Korfmacher, 2003).  Lead optimization involves chemical modification of 
promising lead molecules in order to improve potency, selectivity, metabolism 
and pharmacokinetic parameters (K. C. Cheng, Korfmacher, White, & Njoroge, 
2008; Hughes et al., 2011). 
 Different docking methodologies reproduce the crystallographic binding 
pose to near perfection but struggle while docking novel ligand to the pocket. 
Hence, lead optimization can be achieved by accurate prediction of receptor-
ligand binding affinities and poses. One of the most commonly used 
methodologies is the application of molecular dynamics to the selected lead like 
molecules in order to predict poses and binding free energy. It has been found that 
rescoring poses generated from docking increases the correlation with the 
experimental results (Guimarães & Cardozo, 2008; Lindstrom et al., 2011). 
 





Pharmaceutical Data Exploration Laboratory (PaDEL) excels in 
development and application of methods and tools in the biomedical and 
pharmaceutical fields. The research in PaDEL can be divided into drug discovery, 
clinical informatics, public health informatics and metabonomics. This study 
intends to contribute in the drug discovery project leading to discovery of novel 
drugs against neuraminidase and MCL-1. 
The first objective is to discover pan neuraminidase inhibitors. Majority of 
the drug discovery projects on neuraminidase have focused on a single mutation 
belonging to either group I or group II neuraminidase. However, mutations 
causing resistance against oseltamivir or both oseltamivir and zanamivir are not 
restricted to any specific group. Thus, there is need to develop inhibitors which 
can be effective against neuraminidase irrespective of mutation or group. The first 
step is to build QSAR model to screen probable neuraminidase inhibitor. A 
number of QSAR models have been developed but to the best of my knowledge 
none of them has considered mutations belonging to both groups of 
neuraminidase. Moreover, most of the QSAR models built till date lack 
applicability domain thereby having low reliability. Hence, a consensus QSAR 
model with applicability domain will be built to screen probable neuraminidase 
inhibitors. Structure based drug design is an important part of most of the drug 
discovery projects. Hence, the second aim to achieve the first objective is to do 
structure based screening using various docking protocols. This will help us to 
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find a possible solution to the resistance in neuraminidase and help to develop 
even more potent drugs in future. 
Apoptosis plays an important role in cancer and most of the tumors have 
increased levels of anti-apoptotic proteins. This has led to the development of 
drugs targeting anti-apoptotic proteins. However, challenging binding site of the 
anti-apoptotic proteins have led to only few moderately active inhibitors. 
Moreover, the resistance to these inhibitors due to overexpression of MCL-1 has 
been a cause of concern. Many studies have been performed to develop selective 
MCL-1 inhibitors. In recent study compounds with rhodanine scaffold have 
shown promise as MCL-1 inhibitor. However, the function of the rhodanine 
scaffold is not understood. Hence, the second objective is to analyze the role of 
rhodanine scaffold in selective inhibition of MCL-1 in order to guide the 
development of more potent and selective MCL-1 inhibitors. In order to achieve 
the second objective the compounds belonging to four different classes i.e. 
rhodanine, thiazolidinedione, thiohydantoin and hydantoin were prepared by 
scaffold hoping. The substituents of the compounds were selected for direct 
comparison with the compounds having rhodanine group. This comparison will 
help us to understand the role of rhodanine in MCL-1 inhibition as well as 
develop potential drugs in future.  
The above mentioned objectives of the study will provide exposure to the 
different aspects of the computer aided drug design such as QSAR, docking, 
molecular dynamics. Moreover, two different targets, with different type of 
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pockets, i.e. deep and hydrophobic, shallow and surface groove, will help me to 
get experience in handling different problems.  
  







This chapter describes three possible components of CADD: QSAR (2.1), 
docking (2.2) and molecular dynamics (2.3). These sections also describe the 
methodology applied in our study. The specific parameters, if any, used during a 




In our study, the QSAR modeling consisted of following steps (Figure2.1) 
1. Dataset selection and curation 
2. Descriptor calculations 
3. Descriptor selection 
4. Base model development 
5. Internal validation 
6. Consensus model development 
7. External validation 
8. Prediction i.e. Screening of chemical library 
 




Figure2.1 General workflow of QSAR 
 
 




Figure2.2 k-nearest neighbor 
 
 
Figure2.3 Support Vector Machine 
Kernel function (Ø) SVM converts non-linear classification into linear classification 
 
 
Figure2.4 Five-fold cross validation 
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 Data selection and curation 2.1.1
 
QSAR model depends on the descriptors, which in turn depends on the 
structures of compounds in the dataset. Since accuracy of any model depends on 
the quality of data, any error in the structure will translate into error in the 
descriptors, leading to inaccurate models.  
Some of the steps followed in our study for data curation are removal of 
the data that cannot be handled by cheminformatics techniques, e.g., inorganic 
and organometallic compounds, counterions, salts and mixtures; structure 
validation; ring aromatization; analysis of tautomeric forms; and removal of 
duplicates (Alexander Tropsha, 2010).  
 Descriptor calculation 2.1.2
 
Molecular descriptors are key features of compounds in mathematical 
values that describe the structure or shape of molecules in order to predict the 
activity and properties of molecules (Todeschini & Consonni, 2000). The choice 
of descriptors plays an important role in ligand-based lead discovery. Descriptors 
can be classified according to 1) their dimension and 2) the properties of the 
chemical that they represent. According to dimension, descriptors can be 
classified as 1D, 2D and 3D. 1D descriptor are calculated from the formula itself 
e.g. number of atoms, molecular weight and 2D descriptors are calculated from 
2D structure e.g. number of hydrogen bonds and 3D descriptors are calculated 
from 3D structure e.g. molecular volume, surface area etc. Descriptors derived on 
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the basis of property used such as physicochemical e.g. logP and pKa, electronic 
e.g. polarity and polarizability, topological e.g. connectivity and Weiner index, 
geometrical e.g. length, width and molecular volume etc and complex e.g. BCUT, 
WHIM and 3D-MoRSE (Nikolova & Jaworska, 2003; Todeschini & Consonni, 
2009; Xue & Bajorath, 2000) 




A good QSAR model requires a subset of relevant descriptors. However, 
before selecting a subset of descriptors, a pre-processing step is performed. The 
descriptors were normalized to ensure that all attributes have equal influence on 
the model.  
A large number of descriptors are not recommended (Dudek, Arodz, & 
Gálvez, 2006) (Shahlaei, 2013) as: 
1. Only some of the descriptors are significantly correlated with the 
activity 
2. Many descriptors are intercorrelated. 
3. Prediction accuracy of model might be improved through 
exclusion of redundant and irrelevant descriptors. 
4. Including too many descriptors may lead to overfitting of the 
model 
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5. With less number of descriptors the interpretability of relationship 
between the descriptors and observed activity might be increased. 
Hence, an appropriate subset of the descriptors was identified by feature 
selection to develop the model. 
 Selection 2.1.3.2
 
Descriptor/feature selection is a step to reduce the dimensionality by 
removing irrelevant data. This can lead to increased learning accuracy, and 
improved result comprehensibility (Lei Yu & Liu, 2003). Feature selection can be 
supervised or unsupervised. Supervised feature selection can be divided into three 
general categories i.e. filter methods, wrapper methods and embedded methods 
(Guyon & Elisseeff, 2003; Saeys, Inza, & Larranaga, 2007). Wrapper method 
works by selecting subset of the features by search algorithm and then testing the 
performance of the selected subset by the modeling algorithm (Soto, Cecchini, 
Vazquez, & Ponzoni, 2008). The performance is tested by cross validation or 
validation set. The feature subset with best performance is selected to build the 
model. Forward selection, backward elimination, simulated annealing, tabu 
search, genetic algorithm (GA) are some of the examples using this methodology 
(Gammerman, 2014; Goodarzi, Dejaegher, & Vander Heyden, 2012). Wrapper 
methods use modeling algorithm as a blackbox thus making it simple and 
universal in approach (Guyon & Elisseeff, 2003). Hence, in our study, GA, which 
is one of the wrapper methods, was used for descriptor selection. 
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2.1.3.2.1 Genetic Algorithm 
 
GA belongs to the class of evolutionary algorithms and is based on laws of 
genetics and biological evolution and can be divided into following steps (Leardi, 
2007; Thede, 2004): 
1. Initialization: Create large population of random descriptor 
subsets, represented by binary chromosomes that indicate whether 
a descriptor is selected. 
2. Evaluation: Each chromosome is evaluated and assigned a fitness 
score. Fitness score is a measure of how well a set of descriptor 
can predict the properties. 
3. Selection: In order to improve the fitness of the population two 
members are selected from the current population. The chance of 
being selected is proportional to the chromosomal fitness.  
4. Crossover:  Crossover is performed to exchange descriptors 
between two members hoping to achieve descriptor set with better 
prediction power 
5. Mutation:  In order to add a little bit randomness into the 
population, mutation is performed. It is performed by changing the 
binary value of few descriptors selected randomly. 
6. Repeat: Repeat step 2 to 5 until a new population of N members 
has been created. 
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 Model development 2.1.4
 
The QSAR model that we developed in our study used the following 
procedure: (1) Construct many base models using different descriptor subsets and 
different modeling methods; (2) Select suitable base models to construct a 
consensus model; (3) Evaluate the performance of the consensus model.  
 Model development began by splitting the dataset into 4:1 ratio. The four 
parts were combined to form training set while the 5th part comprised external 
validation set. Training set was used to develop base models. Base models are 
individual predictive models that were combined to form consensus model. In this 
study, base models were constructed from the training set using different 
descriptor subsets and different modeling methods. The different descriptor 
subsets were obtained using a GA process. During the GA process, models were 
developed and evaluated by calculating their Matthew’s correlation coefficient 
(explained in section 2.1.5.3) (Vihinen, 2012) using a 5-fold cross validation 
(explained in section 2.1.5.1 ) process in order to identify relevant descriptors.  
The GA process was repeated several times while the performance, i.e. Matthew’s 
correlation coefficient (MCC), of each model being evaluated using 5-fold cross 
validation. All the models having 70% MCC were added to the model pool. 
In general, methods for building a QSAR model i.e. modeling methods 
can be divided into classification and regression methods. Classification method 
is used to predict the class of the members like inhibitor/non-inhibitor of the 
dataset screened by QSAR.  On the other hand, regression analysis estimates 
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relationships between dependent (response or outcome) variable and one or more 
independent (predictor or input) variables and is used for predicting outcomes 
such as IC50 (Gramatica, 2010; Yee & Wei, 2012). For regression analysis, 
absolute value and minimum error are required. However, this is not available in 
most of the biological activity assay results, for example inactive compounds are 
mentioned as having IC50 greater than 100 µm. Hence, in our study, classification 
methods such as kNN and SVM were used for the development of base models.  
 k nearest neighbor 2.1.4.1
 
k nearest neighbor (kNN) is one of the easiest modeling methods and is 
the first choice when there is little or no prior knowledge about the distribution of 
the data. kNN works by measuring the distance between the test compound to 
every compound in the training set. The two most common measures to calculate 
distance are Euclidean distance and Manhattan distance. The class represented by 
majority of the k number of closest members is returned as the class of test 
compound (Figure2.2) (Yee & Wei, 2012). 
As kNN decision is based on a small neighborhood of similar objects it 
performs well with multi-modal classes. However, treatment of all the features 
equally can lead to classification errors, especially when only a small subset of 
useful features is present (J. Kim, Kim, & Savarese, 2012). 
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 Support Vector Machine 2.1.4.2
 
 SVM is one of the most well-known kernel based method for model 
development. It is based on the concept of decision planes that define decision 
boundaries. In a binary classiﬁcation problem the data can be linearly separable or 
nonlinearly separable. For a linearly separable data, SVM builds a maximal 
margin hyperplane to separate the two classes. While for nonlinearly separable 
data, SVM uses a kernel function to map the vectors into a higher dimensional 
feature space (Figure2.3) in order to make them linearly separable (Yee & Wei, 
2012). 
A main advantage of SVM is that it performs well on datasets having 
many attributes, even with few samples for the training process. However, main 
drawbacks of SVM are limitation in speed and size and the selection of the kernel 
function parameters (J. Kim et al., 2012). 
 Applicability domain (AD) 2.1.4.3
 
All base models had inherent AD which is among the five benchmarks set 
by OECD for any standard QSAR model (Gramatica, 2007).  AD has been 
considered important part of model development by many studies and can be 
defined as the chemical space where a model can predict properties of compounds 
with certain accuracy (Jaworska, Aldenberg, & Nikolova, 2004; Jaworska, 
Nikolova-Jeliazkova, & Aldenberg, 2005; Netzeva et al., 2005; Alexander 
Tropsha & Golbraikh, 2007; Weaver & Gleeson, 2008).  
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AD is the chemical space where a model can be used to predict the 
properties of compounds (Jaworska et al., 2005; Alexander Tropsha & Golbraikh, 
2007; Weaver & Gleeson, 2008). In this study, the AD of each base model was 
defined using the method proposed by Fumera et al (Giorgio Fumera, Fabio Roli, 
& Giacinto, 2000). This multiple thresholds method uses a value that is computed 
by modeling methods to specify the confidence for each prediction. Different 
modeling methods have different algorithms to compute this confidence value. 
For example, in kNN, the confidence value for predicting a compound as an 
inhibitor is computed as the proportion of k nearest neighbors of the compound 
that are inhibitors. So if k is 5 and the number of nearest neighbors of the 
compound that are inhibitors is 4, the confidence value that the compound is an 
inhibitor will be 0.8. Usually in a binary classification modeling method, a 
threshold of 0.5 for the confidence value is used such that if the confidence value 
is more than 0.5, the compound will be predicted as an inhibitor. Otherwise, it 
will be predicted as a non-inhibitor. In the multiple thresholds methods, two 
thresholds are used such that if the confidence value is greater than the higher 
threshold value, the compound will be predicted as an inhibitor. Conversely, if the 
confidence value is smaller than the lower threshold value, the compound will be 
predicted as a non-inhibitor. When the confidence value lies between the two 
threshold values, the compound will be considered as out of the AD of the model 
and its activity will not be predicted. 
In this study, the two thresholds were determined using the confidence 
values of the compounds in the testing sets of a 5-fold cross validation. The 
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confidence values were sorted and those that were found in both inhibitors and 
non-inhibitors, or those that indicate a transition between inhibitors and non-
inhibitors were identified as potential thresholds. All combinations of threshold 
pairs from the pool of potential thresholds were then tested. The optimum 
threshold pair was identified using three criteria. The first is the accuracy of the 
model for those compounds identified as out of the AD should be the lowest when 
using the optimum threshold pair. The second criterion is the precision of the 
model for those compounds identified as within the AD should be the highest 
when using the optimum threshold pair. The last is the number of compounds 
identified as out of the AD should be the largest when using the optimum 
threshold pair. The three criteria were applied consecutively. If only one threshold 
pair satisfied the first criterion, the process was stopped and that pair was 
identified as the optimum pair. If more than one threshold pairs satisfied the first 
criterion, the second criterion was applied. The third criterion was used only when 
more than one threshold pairs satisfied the second criterion. Ties for threshold 
pairs satisfying the third criterion, if any, were broken randomly.  
 Validation  2.1.5
 
Validation is important in order to make a QSAR prediction reliable. 
Depending upon the dataset used for validation, it can be defined as internal and 
external validation. Though both internal and external validation are important, it 
is shown that external validation can improve the reliability of QSAR prediction 
(Golbraikh & Tropsha, 2002; Alexander Tropsha, Gramatica, & Gombar, 2003). 
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 Internal validation 2.1.5.1
 
Internal validation is performed by a subset selected from the training set. 
Some of the methods used for internal validation are random subsampling, 
bootstrap and cross-validation. Cross validation or n-fold cross validation is most 
popular among them where n is the number of portions in which training set is 
distributed. 
In our study, 5-fold cross validation was performed (Figure2.4). The steps 
involved in 5-fold cross-validation are as follows: 
1. Divide the dataset into 5 equal portions 
2. Combine 4 portions to form the training set to build the model 
3. Use the remaining portion as a testing set to assess the predictive 
performance of the model 
4. Repeat steps 2 and 3 until all the portions has been used as a 
testing set once 
5. Get the average performance of the five testing sets 
 External validation  2.1.5.2
 
Unlike internal validation, the external validation dataset is never used in 
model development. Moreover, it was shown that higher internal validation is not 
necessarily sufficient for accurate prediction of model. In addition, emphasis was 
given on external validation as only way to trust the reliability of QSAR 
(Golbraikh & Tropsha, 2002; Alexander Tropsha, 2010). 
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 Predictive performance 2.1.5.3
 
Prediction by QSAR model can be defined as follows: 
 
Table2.1 Confusion matrix showing the predictions made by QSAR model 
 
 Predicted positive class Predicted negative class 
Positive class True positives (TP) False negatives (FN) 
Negative class False positives (FP) True negatives (TN) 
   
All the base models were then ranked based on their cross-validated MCC 
value and the top ten base models were selected to construct a consensus model 
(explained in section 2.1.6). The performance of the consensus model was then 
evaluated using the validation set. The performance was assessed in terms of TP, 
TN, FP and FN, SE, SP, false positive rate (FPR), false discovery rate (FDR). The 
overall performance was measured by Q and MCC. 
False positive rate: FPR defines expected proportion of FP among 
compounds belonging to negative class. 
𝐹𝑃𝑅 = 𝐹𝑃
𝐹𝑃 + 𝑇𝑁 ∗ 100% 
False discovery rate: FDR defines expected proportion of FP among 
compounds belonging to positive class. 
𝐹𝐷𝑅 = 𝐹𝑃
𝐹𝑃 + 𝑇𝑃 ∗ 100% 
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Sensitivity: SE relates to the model's ability to identify a compound 
belonging to positive class correctly. 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 = 𝑇𝑃
𝑇𝑃 + 𝐹𝑁 ∗ 100 
Specificity: SP relates to the model's ability to identify compound 
belonging to negative class correctly. 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁
𝑇𝑁 + 𝐹𝑃 ∗ 100 
Overall accuracy: is also a statistical measure of how well a QSAR 
correctly identifies compounds belonging to a particular class. Accuracy is the 
proportion of true results of both TP and TN in the population. 
𝑄 = 𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝑇𝑁 + 𝐹𝑃 + 𝐹𝑁 ∗ 100% 
Matthew’s correlation coefficient: The MCC is used to measure the 
quality of binary (two-class) classifications and is regarded as a balanced measure 
which can be used even with classes of different sizes. MCC is a correlation 
coefficient between the observed and predicted binary classifications. 
𝑀𝐶𝐶 = (𝑇𝑃 ∗ 𝑇𝑁)− (𝐹𝑃 ∗ 𝐹𝑁)
�(𝑇𝑁 + 𝐹𝑃) ∗ (𝑇𝑁 + 𝐹𝑁) ∗ (𝑇𝑃 + 𝐹𝑃) ∗ (𝑇𝑃 + 𝐹𝑁) 
In our study, MCC values were used to rank the base models and the top 
ten base models were selected to construct a consensus model. 
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 Consensus model 2.1.6
 
Every modeling method has its own strength and weakness. Combining 
the prediction of the different models reduces the risk of wrong selection by a 
single poor model, enables the use of different models trained with different 
portions of the data, reduces risk of overfitting by individual models, supports 
individual model to be trained on different type of data. In order to have a good 
consensus model, the individual models should be as unique as possible. Diverse 
models can be created by different modeling methods, modeling methods with 
different parameters, different feature selection method etc. In our study, all base 
models were ranked based on their cross-validated MCC value and the top ten 
base models were selected to construct a consensus model. 
The AD of the consensus model was defined based on the prediction of 
the base models. Compounds were defined to be out of the AD of the consensus 
model when all the base models identified the compound to be out of their AD, or 
if there was a tie in the predictions (i.e. an equal number of base models predicted 
the compounds to be inhibitors and non-inhibitors). Otherwise, the compounds 
were defined to be within the AD of the consensus model and were predicted 
based on majority voting of the base models. In addition, confidence values for 
the predictions were also computed using a similar algorithm as described earlier 
using kNN. 
 





Docking is the most important component of the structure based drug 
designing which has been supported by the increase in high-resolution 3D 
structures and techniques like homology modeling techniques along with the 
improvements in docking and scoring technologies (Tuccinardi, 2009). Molecular 
docking has two major roles i.e. to predict the binding mode and to predict the 
binding affinity of a complex (Huang & Zou, 2010). In our study docking was 
used as a means to screen probable inhibitors and deduce their binding poses.  
Docking method in our study involved the following steps i.e. receptor structure 
preparation, identification of active site, ligand structure preparation, docking and 
analysis of the results.   
 Receptor Preparation 2.2.1
 
The 3D structure was downloaded from the protein data bank (PDB) 
(Berman et al., 2000) and prepared for the docking process. The preparation 
involved deletion of natural ligand and water, addition of missing hydrogen 
atoms, termini treatment, correction of protonation sates according to a particular 
pH, energy minimization of the hydrogen atoms keeping heavy atoms fixed. 
 Identification of active site 2.2.2
  
The active site was selected according to the data present in literature. If 
the active site is not explicitly mentioned in literature, residues within 6Å of 
natural ligand were selected as active site. 
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 Ligand preparation 2.2.3
 
 Ligands were prepared within MOE or SYBYL which included prediction 




 Optimized ligands were docked against the receptor using MOE or 
SYBYL. Parameters for the docking were selected according to the problem. 
Ligands were ranked according to the scores generated by the docking. The 
selected poses predicted for the ligands were analyzed to deduce reason behind 
the biological activity of the ligand. 
 Molecular Dynamics 2.3
 
All biological systems are dynamic in nature and cannot be understood 
merely looking at their static structure which is just a snapshot from real 
dynamics (X. Cheng & Ivanov, 2012; Durrant & McCammon, 2011). Molecular 
dynamics was performed in our study as it enables to understand the interactions 
in real time which can give more insights leading o better understanding of the 
biological system. In this study, molecular dynamics was performed by following 
steps: 
1. System Preparation 
2. Minimization 
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3. Heat up system  
4. Equilibration 
5. Production run 
 System Preparation 2.3.1
 
 System preparation is the most important step for any process. A system 
with defects like atomics clashes, missing atoms and improper charge can result 
in dubious results. The aim of system preparation is to: 
1. Add missing atoms via homology modeling 
2. Modify ionization according to the desired pH 
3. Preparation of parameter files for novel residues and molecules 
4. Fix bond 
5. Add hydrogen 
6. Add counterions to neutralize the system  
 Minimization 2.3.2
 
Energy minimization is the first real step in molecular dynamics protocol. 
The purpose of energy minimization is to adjust the system according to a 
particular force field, uniform distribution of solvent (in case of explicit solvent) 
and counter-ions and remove any steric clashes between atoms. It was performed 
in two stages: 
1. Energy minimization of water molecules and counter-ions with 
restraints on the protein and ligand was first performed 
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2. In second step, the entire system was minimized.  
Mostly, energy minimization end up finding local minimum structure. To 
avoid local minimum the system is heated in subsequent step. 
 Heating up the system and equilibration 2.3.3
 
The initial positions of the atoms taken from crystal structure have 
velocity corresponding to absolute zero temperature. The velocity reassigned 
randomly is not an accurate method. Hence, the system is heated from 0K to 
310K over a period of time thus reassigning velocities to particular temperature. 
The gradual increase of the temperature ensures that system has uniform 
temperature. 
 Production run 2.3.4
 
Molecular dynamics can be performed by using three different canonical 
ensembles i.e. microcanonical ensemble (constant N,V,E), canonical ensemble 
(constant N,V,T) and isothermic-isobaric ensemble (constant N,P,T). Any 
ensemble can be selected according to the problem in hand. All biological process 
occurs at nearly constant pressure (e.g., atmospheric pressure). Thus, isothermic-
isobaric ensemble seems like a reasonable choice. In our work production run was 
performed at NPT conditions. As molecular dynamics is a random process, 
multiple trajectories were generated for a conclusive result. 
  






This chapter provides an introduction to influenza virus and 
neuraminidase. The role of neuraminidase in virus life cycle and its importance 
as drug target is also discussed. Influenza, commonly called as flu, is a 
communicable respiratory viral disease that affects mainly nose, throat, bronchi 
and, occasionally lungs. Although flu is often confused with other influenza-like 
illnesses such as common cold during the early phase of infection, it is a more 
severe disease and is caused by a completely different virus (Apisarnthanarak et 
al., 2004; Nicholson, 1992; Yuen et al., 1998). 
 
 Influenza virus 3.1
 
Influenza viruses are enveloped viruses belonging to the family 
Orthomyxoviridae. The influenza virus can be distinguished into three categories, 
influenza A, B and C on the basis of antigenic differences between their matrix 
and nucleoprotein (NP) (Lamb & King, 2001).   
Influenza C is less common and Influenza B is confined to human and 
rarely infects other species (Taubenberger & Morens, 2008). Although both 
influenza A and B co-circulate and have been responsible for epidemics, the 
impact of influenza A has been much higher than influenza B. This is because the 
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lower rate of genetic variability, combined with its limited host range reduces the 
chances of pandemics caused by influenza B (Hay, Gregory, Douglas, & Lin, 
2001). 
 Influenza A 3.1.1
 
Influenza A virus is the most virulent of all three due to greater genetic 
variability and host range such as, such as humans, birds, horses, dogs and pigs. 
Influenza A can be sub-divided into different subtypes according to antigenic 
properties of Hemagglutinin (HA) and Neuraminidase glycoproteins. Numerous 
combinations can be found by the combination of 16 HA (H1–H16) and 9 
neuraminidase (N1–N9) glycoproteins. The neuraminidase is further classified 
into two phylogenetic groups based on sequence analysis: N1, N4, N5 and N8 are 
in group I, while N2, N3, N6, N7 and N9 in group II (Russell et al., 2006).                      
 Structure of Influenza A virus 3.1.2
 
The influenza virus consists of a lipid membrane derived from the host 
cell comprising of three surface proteins, the HA, neuraminidase and membrane 
ion channel (M2) protein (Figure3.2). Enclosed inside the lipid membrane are 
internal proteins which includes NP, the matrix protein (M1) and the RNA 
dependent RNA polymerase complex (RPC) composed of polymerase basic 
protein 1 (PB1), polymerase basic protein 2 (PB2) and polymerase acidic protein 
(PA) and two nonstructural proteins, nonstructural protein 1 (NS1) and 
nonstructural protein 2 (NS2) (Swayne, 2008). 
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HA is a trimer composed of a globular domain and a stem domain. HA has 
receptor binding site responsible for the attachment of the virus to the cell sialic 
acid (SA) receptors and fusion peptide responsible for fusion of the viral and cell 
membrane (Wiley & Skehel, 1987). 
Neuraminidase is an enzyme made up of four co-planar and roughly 
spherical and identical subunits. Each subunit consists of head, which possesses 
enzymatic activity, along with a centrally attached stalk. The stalk is embedded in 
the viral membrane by a hydrophobic region. The enzyme is an exo-
glycohydrolase and cleaves α‑ketosidic linkage between terminal sialic acid and 
an adjacent sugar residue (Air & Laver, 1989; Colman, 1994). 
Membrane ion channel protein (M2) is a single-pass membrane protein. 
The function of M2 is to reduce the pH across the viral membrane to allow the 
fusion of viral and endosome membrane. (Pielak & Chou, 2011). 
 Virus life cycle  3.1.3
 
Like all viruses influenza virus need the biological machinery of the host 
cell for its replication (Figure3.3). To achieve this, the virus needs to enter the 
cell. The attachment of influenza virus to the cell is initiated by the interaction 
between the HA and SA receptors present on cell surface. The attachment is 
followed by the internalization of the virus by the process of endocytosis. During  




Figure3.1 General symptoms of Influenza (Häggström, 2014) 
 
Figure3.2 Structure of Influenza Virus (Mackay)  




Figure3.3 Overview of influenza virus life cycle (Times, 2007) 
 
Figure3.4 Role of neuraminidase in influenza life cycle (Can005, 2011). 
Neuraminidase plays an important role in virus life cycle and is required for release of budding 
virion from the host cell. Neuraminidase achieves that by cleavage of bond formed between 
hemagglutinin and sialic acid receptors   
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the process of endocytosis drop in pH lead to the fusion of the membrane and 
unpacking of the genome (Ari, 1992; Pinto & Lamb, 2006).The fusion domain 
causes the fusion of viral and endosome membrane followed by the release of 
RNP into the cellular cytoplasm leading to generation of virus progeny (Fodor & 
Brownlee, 2002; Pielak & Chou, 2011). The HA that facilitates the viral entry 
inhibits the release of virion by attaching again to the SA receptors. 
Neuraminidase cleaves of α(2-6) ketosidic linkage between a terminal SA and an 
adjacent sugar residue thus releasing the budding virions and blocking them to get 
clumped with each other (Figure3.4). 
 Antigenic variation  3.1.4
 
Antigenic variation in influenza viruses occurs by mainly two mechanisms 
(Figure3.5) (Hay et al., 2001; Nelson & Holmes, 2007) i.e. point mutations 
(antigenic drift) and gene reassortment (antigenic shift). 
 Antigenic Drift 3.1.4.1
 
Antigenic drift is caused due to the accumulation of point mutations in 
viral proteins. The high rate of mutation is the result of low accuracy of RNA-
dependent RNA polymerase. The viruses having certain advantages over other are 
selected. Eventually this leads to changes sufficiently large enough to avoid 
existing antibodies. Antigenic drift happens while a single type of virus passes 
through the host. 
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 Antigenic Shift 3.1.5
 
The genetic shift occurs when two viruses, having property to infect two 
different hosts, co-infect a single host e.g. swine. The selectivity of a virus 
depends on the type of SA acid linkage present in a host. The SA has α(2,6) 
linkage in humans and have α(2,3) linkages in case of avians and equines while 
swine has SA with both type of linkages (Kimble, Nieto, & Perez, 2010). As 
genome of the influenza virus is segmented, reassortment of the genome between 
two strains of viruses results in a new strain. This new strain can have the 
capability to infect human but due to genetic reassortment is significantly 
different to avoid immune response. 
 Characteristic function of Neuraminidase  3.1.6
 
The role of neuraminidase is to catalyze the cleavage of α(2-6) - or α(2-3)-
ketosidic linkage that exists between a terminal SA and an adjacent sugar residue. 
This removal of SA has two major effects. Firstly, it assists in the mobility of 
virus in the respiratory tract as well as facilitates the release of virion progeny 
from infected cells. Secondly, the removal of SA from the carbohydrate moiety of 
newly synthesized HA and neuraminidase is necessary to prevent self-aggregation 
of the virus after release from host cells (Air & Laver, 1989; Gong, Xu, & Zhang, 
2007).  In addition, neuraminidase plays an important part in secondary infection 
such as bacterial pneumonia possibly by the destruction of respiratory epithelium; 
virus-induced immunosuppression; and inflammatory response to viral infection 
(Gong et al., 2007). 





Figure3.5 Schematic representation of different ways causing virus mutation (NIAID, 2011). 
In step B the virus is transferred from the bird to the human directly. The virus leaving the human 
have gained some mutation by the process of genetic drift. Genetic drift also leads to mutation on 
path C where virus is first transferred to swine and then later to humans. However, the virus 
specific to bird (A-1) and human (A-3) infect common host swine in step A-3. This leads to new 
strain of virus having capability to infect human but with different antigen to avoid immune 
system by the process of genetic reassortment.  
  




Figure3.6 Neuraminidase tetramer [2HTY] 
 
             a) 
 
 
                b) 
Figure3.7 Neuraminidase group 1 monomer depicting putative active site, 430 loop and (a) closed 
150 loop [2HU4] and open 150 loop [2HTY]  
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 Neuraminidase as a drug target 3.1.7
 
M2 ion channel allows the uncoating of virus particles in endosome and 
thus plays a crucial part in virus life cycle. Considering its important role, M2 ion 
channel was the first target for influenza treatment. However, the M2 inhibitors 
were effective against influenza A infection as only the A strains of the virus have 
M2 ion channel proteins. Moreover, cases of CNS side effects and drug-resistant 
viral strains were reported against M2 inhibitors (Q. Liu, Liu, & Yang, 2013; 
Mark von Itzstein, 2007). This resulted in the hunt for other possible targets for 
influenza treatment. Neuraminidase is another protein that plays crucial role in 
virus life cycle and has been considered as a prime target for influenza inhibitors. 
As can be seen from Figure3.4 neuraminidase inhibitors halts the release 
of budding influenza viruses from infected host cells thereby preventing infection 
of new host cells and interrupting the infection (Moscona, 2008).  Studies have 
revealed that despite low sequence identity, the structure is well conserved among 
group I and II as well as neuraminidase of influenza B virus. Moreover, the active 
site is more or less conserved among all neuraminidase (Russell et al., 2006).  
 Structure of neuraminidase 3.1.8
 
  The structure of neuraminidase was deduced by Varghese, Laver and 
Colman for N2 subtype (J. N. Varghese, Laver, & Colman, 1983). According to 
them, neuraminidase is a mushroom-shaped tetrameric protein (Figure3.6), 
attached to the viral membrane by slender stalk composed of hydrophobic 
sequence at N-terminus. The enzyme active site and calcium binding domain are 
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situated in the head of neuraminidase. The neuraminidase's head region is 
propeller-like structure formed by six blades. Each blade is formed of four anti-
parallel β sheets stabilized by disulfide bonds. Blades are connected by loops of 
variable length and structure. (Air, 2012; Gong et al., 2007; Shtyrya, 2009) 
   Active site of neuraminidase 3.1.9
 
There is up to 75% sequence variation but the active site is highly 
conserved in most influenza A and B viruses and there are large numbers of 
charged residues in the pocket enclosing SA binding site also known as SA cavity 
(Gong et al., 2007). However, group-1 and group-2 neuraminidase differ from 
each other centered on the 150-loop (residues 147–152). A major consequence of 
these differences in structure is that there is a large cavity (150-cavity) adjacent to 
the active site in group-1 but not in group-2 neuraminidase (Figure3.7). This 
leads to an increase in width of the active site cavity by about 5Å in group-1 
viruses (Russell et al., 2006).  
It has been found in the apo simulations of group-1 neuraminidase that 
motion is coupled to an outward movement of the adjacent 430-loop (residues 
430-439). This had led to two additional cavities in group-1 neuraminidase 
besides SA cavity i.e. 150-cavity and 430 cavity which has been explored to 
identify potential residues for novel drug interactions (Amaro et al., 2007; L. S. 
Cheng et al., 2008; Landon et al., 2008). 
Out of the residues comprising the active site, eight amino acids i.e. 
Arg118, Asp151, Arg152, Arg224, Glu276, Arg292, Arg371, and Tyr406 are 
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referred as catalytic residues due to their critical role for functioning and their 
direct contact to the substrate, while eleven others i.e. Glu119, Arg156, Trp178, 
Ser179, Asp198, Ill222, Asp227, Asp277, Asn294, and Asp425 are known as 
framework residues due to their primary role in stabilization of the active site 
(Ferraris & Lina, 2008). Catalytic residues, except Arg224, are in direct contact 
with sialic acid and form polar contacts. Arg224 forms nonpolar contact with the 
glycerol moiety of the N-acetylneuraminic acid (Neu5Ac2en) (Shtyrya, 2009).  
 





Arg118, Glu119, Leu134, Val149*, Lys150*, Asp151, Arg152, Ser153, 
Pro154, Arg156, Trp178, Ser179, Ser195, Gly196, Ile222, Arg224, Glu227, 







Val116, Ile117, Arg118, Leu134, Thr135, Gln136, Ser145, Gly147, Thr148, 







Asn325, Pro326, Tyr347, Asn369, Ser370, Arg371, Trp403, Ser404, 
Tyr406, Ile427, Arg428, Gly429, Arg430, Pro431, Lys432, Glu433, Ile437, 
Trp438, Thr439 
 
Binding cavity residues are sorted according to the location in different cavities. Residues in bold 
face participate in interactions in more than one cavity across cavity boundaries  
  
On the basis of the occurrence of residues at SA cavity, 150 loop or 430 
loop Cheng et al. classified the residues as shown in Table3.1. While some 
residues are restricted to a particular loop or pocket, other are shared between two 
cavities. Moreover residues such as Val149 and Lys150 are present in 150 cavity 
but form a part of SA cavity as 150 loop attains closed conformation. 
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 Neuraminidase inhibitors 3.1.10
 
The mechanism of neuraminidase action proceeds via formation of a 
sialosyl cation intermediate. This catalytic intermediate is subsequently released 
as α-Neu5Ac (Mark von Itzstein, 2007). C-1 carboxylate group α-Neu5Ac  and 
Neu5Ac2en forms charge–charge interactions with positively charged arginine 
triad i.e. Arg118, Arg292 and Arg371 (M. von Itzstein & Thomson, 2009).  As a 
result, a number of Neu5Ac2en mimetic was discovered as potential 
neuraminidase inhibitors. Among these, 2‑deoxy‑2,3-didehydro‑N-
acetylneuraminic acid (DANA) proved to be the most potent inhibitor. The 
deduction of apo and holo crystal structures with ligands α-Neu5Ac and 
Neu5Ac2en turned out to be critical in the discovery of neuraminidase inhibitors 
(Colman, Varghese, & Laver, 1983; J. N. Varghese et al., 1983; J. N. Varghese, 
McKimm-Breschkin, Caldwell, Kortt, & Colman, 1992). By applying structure 
based drug design, the most potent neuraminidase inhibitor 4-deoxy-4-guanidino-
Neu5Ac2en i.e. zanamivir was discovered. However, due to its poor 
bioavailability, intraoral inhalation was chosen for drug delivery (Mark von 
Itzstein, 2007; M. von Itzstein & Thomson, 2009).  
The discovery of zanamivir provided valuable details and laid the 
foundation of other neuraminidase inhibitors such as GS4071 (Figure3.8). The 
crystal structure of GS4071 revealed that the orientation of the cyclohexene ring 
and key interactions involving the carboxylate, amino and acetamido substituents 
with the neuraminidase active site are similar to those observed for Neu5Ac2en 
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and its derivatives (C. U. Kim et al., 1997; C. U. Kim et al., 1998). The pentyloxy 
side chain occupied the region utilized by glycerol group in zanamivir. This was 
possible due to the reorientation of Glu276 thus creating a hydrophobic cavity. 
However, GS4071, similar to zanamivir, had poor bioavailability and thus its pro-
drug was used. This ethyl ester pro-drug is known as oseltamivir (Mark von 
Itzstein, 2007; M. von Itzstein & Thomson, 2009). 
  












 Drug resistance 3.1.11
 
Both zanamivir and oseltamivir resemble the natural substrate. It was 
believed that due to this close resemblance, they are less likely to face resistance. 
However, several mutations have been observed to cause resistance against one or 
both of them (Abed, Baz, & Boivin, 2006; Ferraris & Lina, 2008; Richard et al., 
2008). Currently three major neuraminidase mutations i.e. H274Y, N294S in N1 
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The R292K mutation have been shown to compromise viral growth and 
reduced neuraminidase catalytic efficiency (Yan Wu et al., 2013) but the H274Y 
and N294S mutations are stably maintained. The high resistance against 
oseltamivir due to H274Y and R292K in N1 and N9 respectively has caused 
major concerns (Collins et al., 2008; Woods, Malaisree, Long, McIntosh-Smith, 
& Mulholland, 2013; Yan Wu et al., 2013). A number of studies has been 
conducted to deduce the mechanism behind the oseltamivir and zanamivir 
resistance due to various mutations in order to develop better neuraminidase 
inhibitors (Chachra & Rizzo, 2008; Collins et al., 2009; Aeron C. Hurt, Lowther, 
Middleton, & Barr, 2010; Karthick & Ramanathan, 2014; Malaisree et al., 2009; 
Mihajlovic & Mitrasinovic, 2008; J. W. Park & Jo, 2009; Shu et al., 2011; 
Vergara-Jaque et al., 2012; Woods et al., 2012). However, not much success has 
been achieved and pan neuraminidase inhibitor remains a dream.   






This chapter describes methods used to achieve our goal to discover pan 
neuraminidase inhibitors. Consensus QSAR model (4.1) with AD was built to 
screen ZINC library for probable neuraminidase inhibitors (PNI). The probable 
inhibitors were docked (4.2) against group I and group II neuraminidase with 
open, closed conformations. The three most important mutations, i.e. H274Y, 
N294S and R292K, resulting in resistance against all three influenza drugs i.e. 




 Dataset curation 4.1.1
 
The literature was extensively surveyed to obtain as many structurally 
diverse inhibitors of influenza A neuraminidase group I (NA1) with their 
respective IC50 values. A total of 279 NA1 inhibitors were obtained (Abed, 
Nehme, Baz, & Boivin, 2008; Dao et al., 2011; Dao et al., 2010; Honda, Masuda, 
Yoshida, Arai, Kaneko, et al., 2002; Honda, Masuda, Yoshida, Arai, Kobayashi, 
et al., 2002; A. C. Hurt et al., 2007; C. U. Kim et al., 1998; Lew et al., 2000; Lew 
et al., 1998; A. L. Liu, Wang, Lee, Wang, & Du, 2008; Y. Liu et al., 2011; 
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Masuda, 2003; Rao et al., 2010; Shie et al., 2007; Smith et al., 1998; Sun, Zhang, 
Huang, & Zhou, 2006; Wen et al., 2010; Williams et al., 1997; Yamashita et al., 
2009). The 2D structures of the inhibitors were drawn using ChemDraw Pro 12.0 
(ChemDraw, 2011) and then processed using Pipeline Pilot student edition 
(Pipeline, 2011), following the general guidelines suggested by recent reviews on 
the importance of data curation in QSAR modeling work (Dearden, Cronin, & 
Kaiser, 2009; Fourches, Muratov, & Tropsha, 2010). The process started with the 
removal of compounds containing one or more metal atoms as the majority of 
chemical descriptors cannot be calculated reliably for such compounds. The 
protonation states of common functional groups were set according to pH 6.5, 
which is the standard assay conditions for neuraminidase assays (L. S. Cheng et 
al., 2008; Garozzo, Timpanaro, Stivala, Bisignano, & Castro, 2011). Compounds 
with several tautomeric forms were standardized to a single tautomer. The 
compounds were then energy minimized using the default settings in Pipeline 
Pilot energy minimization component. Duplicate compounds were identified by 
generating canonical SMILES string for each compound and removing those 
compounds with duplicate canonical SMILES string. For enantiomeric pairs, the 
enantiomer with the higher IC50 value was removed because only 1D and 2D 
chemical descriptors will be calculated and such descriptors cannot discriminate 
between the enantiomers. This reduced the number of NA1 inhibitors to 264.  
The inhibitors were then divided into two groups based on their IC50 
values. A total of 173 compounds with IC50 values ≤ 10 µM were placed in the 
potent inhibitors group, and 91 compounds with IC50 values > 10 µM were placed 
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in the weak inhibitors group. In order to increase the diversity and size of the 
dataset, 1326 drugs from FDA Orange Book were obtained and processed in the 
same manner as the NA1 inhibitors. Drugs that were known neuraminidase 
inhibitors were removed. A similarity check protocol based on Tanimoto 
coefficient in Pipeline Pilot was also performed to remove those drugs that were 
very similar to the NA1 inhibitors. The remaining 1224 drugs were considered as 
non-inhibitors and were combined with the weak inhibitors group to form the 
weak/non-inhibitors group (henceforth referred to as non-inhibitors for brevity). 
A training set and a validation set were formed from the two groups by 
splitting the compounds in the groups in a ratio of 8:2. The training set was used 
to develop the QSAR models and contained 138 potent inhibitors and 1052 non-
inhibitors. The validation set was used to determine the prediction performance of 
the final QSAR model and contained 35 potent inhibitors and 263 non-inhibitors. 
 Descriptor calculation  4.1.2
 
A total of 672 1D and 2D different molecular descriptors were calculated 
using PaDEL-Descriptor v2.7 (Yap, 2011). These include descriptors from 
different classes such as autocorrelation descriptors (e.g. autocorrelation 
(charge)); chi indices descriptors (e.g. chi chain); electrotopological state indices 
descriptors (e.g. atom type electrotopological state); BCUT descriptors; 
constitutional descriptors (e.g. weight, ring counts); topological descriptors (e.g. 
Zagreb index, Wiener numbers). Descriptors with zero standard deviation in their 
values were then removed. 
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 Development of QSAR model and screening    4.1.3
 
The models were built according to the method defined in chapter 2 with 
following parameters. For kNN, different k values were used and these include 3, 
5, 7, 9, 11 and 13. For SVM, γ used were 0, 0.02, 0.0002, 0.000002, 0.00000002 
with C = 100000. 
In order to identify novel neuraminidase inhibitors, the ZINC library 
containing 26 million compounds were screened with the consensus model.  
 Docking 4.2
 
 Structure preparation 4.2.1
 
 Both group I and II neuraminidase crystal structures were downloaded 
from PDB. These include N1 crystal structures with open and closed loop, H274Y 
and N294S mutation (henceforth referred as N1_open, N1_closed, N1_H274Y, 
and N1_N294S respectively) and N9 crystal structures (N9_closed, N9_R292K). 
The neuraminidase strains used in this study and their corresponding PDB files 
can be found in Table4.1. 
Calcium has an important role in the enzymatic activity of neuraminidase 
and its use in docking studies has been suggested (Lawrenz et al., 2010). Among 
the structures used in the study only N1_closed and N1_N294S lacked calcium 
ion. Hence, a calcium ion was added to N1_closed and N1_N294S by 
superimposing it to N1_open and placing a calcium ion in the same location as in 
   




Table4.1 Neuraminidase strains used for docking study 
 










(Russell et al., 
2006) 
Susceptible Susceptible Susceptible 
N1_closed 2HU4 
(Russell et al., 
2006) 
Susceptible Susceptible Susceptible 
N1_H274Y 3CKZ 
(Collins et al., 
2008) 
Resistant Susceptible Susceptible 
N1_N294S 3CL2 (Collins 
et al., 2008) 
Low resistant Susceptible Susceptible 






Susceptible Susceptible Susceptible 
N9_R292K 4MWL (Yan 
Wu et al., 
2013) 
Resistant Low resistant Low resistant 
 
N1_open. Ligands and water molecules were deleted from PDB structures and the 
resulting structures were prepared using MOE and SYBYL (SYBYL-X). 
Structure preparation includes structure correction, protonation and energy 
minimization. The protonation states were determined at pH 6.5, which is the 
standard assay condition for neuraminidase assays (L. S. Cheng et al., 2008; 
Garozzo et al., 2011). The calculation of partial charges and energy minimization 
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of only hydrogen atoms was performed using AMBER99 within MOE and 
SYBYL. 
 Active site 4.2.2
 
In our study, residues described by Lily et al., (L. S. Cheng et al., 2008) 
were used defined active site. For receptors with closed 150 loop, residues of SA 
cavity i.e. R118, E119, L134, V149, K150, D151, R152, S153, P154, R156, 
W178, S179, S195, G196, I222, R224, E227, S246, E276, E277, R292, N294, 
Y347, R371, Y406 constituted the active site. In addition, residues from 150 and 
430 cavity i.e V116, I117, T135, Q136, S145, G147, T148, N325, P326, N369, 
S370, W403, S404, I427, R428, G429, R430, P431, K432, E433, I437, W438 and 
T439 were used to define the active site for the structures with open 150 loop.  
 Dataset for virtual screening 4.2.3
 
 Compounds predicted as PNI as result of screening by QSAR model was 
used for virtual screening (N. Sharma & Yap, 2012). In addition, oseltamivir and 
zanamivir, the two well-known neuraminidase inhibitor, as well as laninamivir 
were added to the library. 
 Molecular docking 4.2.4
 
 Docking was performed in two stages i.e. filtering compounds that are by 
a less exhaustive approach and exhaustive search against various mutant strains 
(Figure4.1).  It has been mentioned in many studies that 150 loop closes after 
binding to ligand which enables it to make tighter interaction with the ligand 
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(Russell et al., 2006; M. Wang et al., 2011; Yan; Wu et al., 2013). Hence, the 
preliminary filtering was performed using N1_open. In the first stage docking was 
performed using MOE and SYBYL. The resulting poses were sorted according to 
the docking score and top 50% of the ligands from each were combined to form a 
non-redundant library of compounds. High penalty was opted for ligands leaving 
the active site while docking using SYBYL. The side chains were kept free during 
refinement of the poses while docking with MOE. 
Before moving on to second stages of docking, drug-like filters were 
applied to remove the compound with more likeness to be, for instance, 
bioavailable. The remaining compounds went through second stage of docking. 
Docking was performed against N1_closed, N1_H274Y, N1_N294S, N9_closed 
and N9_R292K using the more rigorous Surflex-GeomX protocol in SYBYL. 
Compounds with score lower than oseltamivir were filtered at every stage of 
docking.  
 Energy minimization and rescoring 4.2.5
 
Considering the amount of time required only top 10 PNI were selected 
for energy minimization. The three best poses for each PNI, selected by visual 
inspection of docking results, were used for energy minimization. Partial charges 
and force field parameters for the compounds were generated automatically by 
antechamber suite in AMBER12 (D.A. Case, 2012). The general AMBER force 
field (gaff) (J. Wang, Wolf, Caldwell, Kollman, & Case, 2004) was used for com-  
 




Figure4.1 Overview of docking process 
 
-pounds, and AMBER ff12SB force field for the proteins. Hydrogen atoms for the 
neuraminidase were added using the LEaP module in AMBER12. Systems were 
solvated using TIP3P (Jorgensen, Chandrasekhar, Madura, Impey, & Klein, 1983) 
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water in a octahedron box extending 12 Å beyond any solute atom. The system 
was made neutral by adding appropriate number of counter ions.  
Energy minimization was performed using pmemd.cuda in AMBER12. 
Water molecules and counter ions were minimized with 500 cycles of steepest 
descent followed by same number of conjugate gradient cycles. This was 
followed by energy minimization of the entire system during which only ligand, 
protein residues within 6Å of ligand and hydrogen atoms were allowed to move, 
maintaining other atoms fixed. The energy minimization of atoms only in 
proximity of the ligand was performed as fully minimized poses could lead to 
different local minima thereby creating noise in analysis (Guimarães & Cardozo, 
2008). The minimized poses were rescored using Autodock (Morris et al., 2009).  




Neuraminidase Results and Discussion 
 
This chapter describes the results for neuraminidase including the 
performance of base models, overall performance of consensus model and the 
compounds predicted outside AD. In addition, results of docking and comparison 
of the poses of approved neuraminidase inhibitors as well as probable inhibitors 




In this work, the first phase of drug design was to develop a QSAR model 
with a defined AD and low FPR for screening large chemical libraries for novel 
and potentially potent NA1 inhibitors. We have developed such a model using a 
multiple thresholds AD method, potent NA1 inhibitors, use of marketed drugs as 
additional non-inhibitors and consensus modeling. 
Only compounds having inhibitory activity against NA1 were collected 
while those having activity against other neuraminidase were not added into the 
dataset to reduce the FPR. It is common to use IC50 ≤ 10 µM to identify potent 
inhibitors (Birchall, Gillet, Harper, & Pickett, 2008; Lange et al., 2010; Naik, 
Santoshi, & Joshi, 2012). Although IC50 ≤ 1 µM has been suggested to identify 
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very potent inhibitors, it would have reduced the number of inhibitors in this 
study, which may reduce the diversity of inhibitors and cause the model to miss 
the identification of substantial numbers of potential inhibitors. Hence, in this 
study, we have decided to use the common threshold of IC50 ≤ 10 µM. In the 
future, when there are more very potent inhibitors available, another QSAR model 
could be developed for the prediction of very potent neuraminidase inhibitors. A 
similar consideration is the use of two cutoff values to ensure better separation of 
inhibitors and non-inhibitors. However, this would have removed a large portion 
of the weak inhibitors from the negative set, which may reduce the AD of the 
model. The use of single cutoff value ensured that the molecules with weak 
activity were categorized as non-inhibitors. Hence, a single cutoff value of IC50 ≤ 
10 µM was chosen to divide the dataset into potent and weak inhibitors.  
There are more published potent NA1 inhibitors than non-inhibitors. 
Models trained using such datasets often had high FPR. Hence, in this study, we 
added marketed drugs to increase the size and diversity of non-inhibitors so as to 
reduce the FPR of the models. The results suggest that such approach is practical 
and useful. A considerably low FPR and FDR of the consensus model increase the 
efficiency to screen large chemical libraries. 
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SE (%) SP (%) MCC 
1 3 227 110 0 1023 0 28 29 0.992 100 99.6 0.980 
2 3 224 110 0 1023 0 28 29 0.991 100 99.6 0.980 
3 3 221 112 0 1023 0 26 29 0.991 100 99.6 0.980 
4 3 228 110 0 1023 0 28 29 0.992 100 99.6 0.980 
5 3 225 110 0 1023 0 28 29 0.991 100 99.6 0.980 
6 5 221 124 3 1039 5 11 8 0.993 97.4 99.5 0.962 
7 5 222 124 3 1039 5 11 8 0.993 97.4 99.4 0.959 
8 5 224 124 3 1039 5 11 8 0.993 97.4 99.4 0.959 
9 5 223 124 3 1039 5 11 8 0.993 97.4 99.4 0.959 
10 5 224 124 3 1039 5 11 8 0.993 97.4 99.4 0.959 
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 Base Models 5.1.1
 
From a total of 38655 base models, top models were selected on the basis 
of their performance (Table 5.1) to form consensus model. Analysis of the base 
models used to construct the consensus model showed that all the base kNN 
models had k as 3 or 5. 
Base kNN models with k > 5 had larger FP and FN. This could be due to 
the fact that though large k yields smoother decision regions (Y. Song, Huang, 
Zhou, Zha, & Giles, 2007), k that were too large are detrimental as it destroys the 
locality of the estimation since farther unrelated compounds are also used for the 
prediction of the unknown compounds (V. C. P. Chen, 2010). Base SVM models 
usually had larger FN, which may have led to the rejection of many novel 
inhibitors. Hence these models were not used to form the consensus model. From 
the initial 672 descriptors, a maximum of 228 descriptors were found to be useful 
for developing the base models.  
 Performance of consensus model 5.1.2
 
The performance of the consensus model on the training set and validation 
set were similar, with an overall accuracy of 99.3% and 98.0% respectively 
(Table5.2). This suggests that the consensus model was unlikely to be overfitted. 
It can be seen that the consensus model has a low FPR, the proportion of 
negative predicted as positive out of total negative compounds available, of 0.8% 
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and low FDR, which is a measure of how many of total positives predicted are not 
TP, of 6.3%. 
Table5.2 Performance of the consensus model 

















Training set 127 3 1042 5 8 5 0.916 97.7 99.5 99.3 0.966 
Validation 
set 30 4 260 2 1 1 0.851 88.2 99.2 98.0 0.898 
 
The numbers of descriptors used in the base models varied between 200 
and 250.  MCC value was calculated as it is less influenced by imbalanced test 
sets due to consideration of accuracy and error rate of both classes (Bekkar, 
Djemaa, & Alitouche, 2013). In comparison to overall accuracy MCC dropped for 
validation set which was more significant for validation set i.e. 0.898 in 
comparison to 0.966.  
 Compounds outside AD 5.1.3
 
AD for a model can be defined in many ways. Some models define AD 
using chemical classes that are found in the training set. In other cases, AD is 
defined using the range of descriptors values or determining the probability 
density. The disadvantage of these AD methods is that the AD is dependent on the 
training set but independent of the modeling method. An improved method is to 
define the AD on the basis of prediction confidence (Tong et al., 2004). This 
allows the AD to be dependent on both the training set and modeling method. 
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Hence, AD of the base models was defined using prediction confidence in this 
study. 
 




Name as in 
reference Chemical class 
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61+ 2H-1,2,4-thiadiazolo [2,3-a] pyrimidine 




































































































bearing a substituted 
pyrimidine ring 
+ From Reference (Sun et al., 2006), *From reference (Abed et al., 2008), ** Drug from 
FDA orange book 
 




 Table 5.4 Functional group present in the compounds outside of AD 















Me : Methyl, Et : Ethyl, Ph: Phenyl, Py: Pyrimidine 
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A total of 13 compounds in the training set and 2 compounds in the 
validation set were outside the AD of the consensus model Table 5.3. Analysis of 
the compounds outside AD of the consensus model reveals that the majority of 
these compounds are of the acyl(thio) urea class with substituted pyrimidine rings. 
Other than substituted pyrimidine rings, other groups were also present in these 
compounds (Table 5.4). 
Screening of the ZINC library using the consensus model identified 64772 
compounds as potential neuraminidase inhibitors. A total of 173674 compounds 
were outside the AD of the consensus model. Most of the identified potential NA1 
inhibitors from the ZINC library have one or more aromatic rings. The scaffold 
connecting the rings had C=S, N-H, and C=O, which may form hydrogen bonds 
in the active site of NA1. 
 Docking 5.2
 
The extensive docking process reduced the number of compounds to 1148. 
The structures of the top 10 PNI selected for energy minimization can be 
observed in (Table5.5). The Tanimoto coefficient was calculated between the top 
10 PNI and established drugs i.e. oseltamivir, zanamivir and laninamivir. The 
patent records were checked for any possible patents of the inhibitors suggested 
by our work.  In addition the inhibitors were inspected for role in any other 
disease. Lastly, commercial availability of the compounds was looked into.  
As can be observed from the (Table5.6) none of the PNI is closely related 
to established drugs. However, PNI were found to be more similar to zanamivir 
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and laninamivir which could be attributed to the presence of guanidino group. 
ZN37 was found to be most similar to all three established inhibitors which can be 
observed by highest tanimoto coefficient of 0.549, 0.609 and 0.307 for zanamivir, 
laninamivir and oseltamivir respectively.  ZN17 and ZN88 were found to be most 
dissimilar compounds in comparison due to lack of central scaffold present in 
other inhibitors. ZN33 and ZN99 are other compounds similar to established 
inhibitors. Despite having guanidino group and central ring similar to zanamivir 
and laninamivir, ZN88 has low tanimoto coefficient of 0.216, 0.194 and 0.189 
against zanamivir, laninamivir and oseltamivir respectively. The tanimoto 
coefficient of ZN46 was also found on lower side. 
As be seen from (Table5.7) that none of the probable inhibitors have been 
reported in literature for any other diseases. However, two compounds ZN21 and 
ZN37 was found to be covered in patent by IBM and Thomson pharma 













Table5.5 The final 10 PNI and their ZINC codes 
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Table5.6 Tanimoto coefficient of the PNI against established inhibitors 
 Zinc Code Zanamivir Laninamivir Oseltamivir 
1 ZN37 0.549 0.609 0.307 
2 ZN33 0.398 0.498 0.291 
3 ZN99 0.537 0.495 0.265 
4 ZN35 0.37 0.46 0.28 
5 ZN21 0.353 0.343 0.217 
6 ZN43 0.332 0.333 0.301 
7 ZN46 0.245 0.294 0.259 
8 ZN88 0.216 0.194 0.189 
9 ZN17 0.157 0.142 0.098 
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Table5.7 Information related to PNI 
 Zinc Code 
Literature 







Bioorg Med Chem 




A None None None 
2 ZN35 
 
Bioorg Med Chem 




A None None None 
3 ZN99 
 
Bioorg Med Chem 




A None None None 
4 ZN21 






















None None None None 
7 ZN37 
 
Bioorg Med Chem 





















None None None None 
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 Energy Minimization and Rescoring  5.2.1
 
Scores generated as a result of energy minimization can be observed in 
Table 5.8. The energy minimization and pose rescoring resulted in decrease of the 
energy for ZN17 and ZN78. The binding free energy of zanamivir and 
laninamivir was found to be close to each other. For all three i.e. oseltamivir, 
zanamivir and laninamivir, lowest binding free energy was found in N9_R292K. 
Besides N9_R292K the binding free energy of zanamivir and laninamivir showed 
no effect of mutation. On the other hand, the binding free energy of oseltamivir 
dropped slightly in N1_N294S and even more in N1_H274Y. Binding free energy 
of the top five PNI were not affected by N1_H274Y and N1_N294S mutation but 
some slight drop was observed in N9_R292K. 
 Standard Deviation of the docking scores 5.2.1.1
 
The standard deviation (SD) of the docking scores was calculated (Table 
5.8) in order to indicate how susceptible the different inhibitors are to different 
mutation environments. The lowest SD was observed for ZN78 but it also had 
lowest average docking score. The SD of ZN43, ZN88, ZN35 and ZN46 was 
found close to each other. Among these four ZN88 had highest average binding 
free energy followed by ZN46, ZN35 and ZN43. Though ZN33 and ZN21 ranked 
2nd and 3rd according to the average binding free energy but they showed higher 
SD in comparison to the above mentioned inhibitors. The highest SD was 
observed for  laninamivir, zanamivir and oseltamivir indicating maximum 
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susceptibility towards mutations. Hence, ZN43, ZN88, ZN35 and ZN46 are least 
influenced by mutations and also has good binding free energy. 
 
Table 5.8  Binding free energy (kcal/mol) of 10 PNI along with oseltamivir, 
zanamivir and laninamivir. 
 
Compound N1_closed N1_N294S N1_H274Y N9_closed N9_R292K ABFE SD 
ZN78 -5.51 -5.17 -5.02 -5.15 -6.01 -5.372 0.4 
ZN43 -9.24 -9.28 -9.7 -8.71 -8.19 -9.024 0.584 
ZN88 -11.17 -11.6 -11.63 -10.64 -10.25 -11.058 0.604 
ZN35 -9.79 -9.61 -10.16 -9.31 -8.5 -9.474 0.625 
ZN46 -9.21 -9.43 -10.7 -9.12 -9.39 -9.57 0.644 
ZN37 -7.49 -8.15 -9.58 -8.04 -8.21 -8.294 0.733 
ZN99 -7.92 -10.13 -9.31 -8.51 -8.93 -8.96 0.833 
ZN33 -10.94 -9.71 -10.61 -10.08 -8.75 -10.018 0.853 
ZN21 -9.02 -10.18 -11.16 -9.21 -8.95 -9.704 0.952 
ZN17 -7.75 -7.7 -5.28 -6.46 -5.99 -6.636 1.079 
Laninamivir -7.65 -8.32 -8.85 -7.57 -5.59 -7.596 1.237 
Zanamivir -8.1 -7.83 -8.73 -7.97 -5.28 -7.582 1.332 
Oseltamivir -8.58 -8.38 -7.72 -8.87 -5.16 -7.742 1.504 
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 Correlation between IC50 and average binding free energy 5.2.1.2
(ABFE) 
 
Table 5.9  Average binding free energy (kcal/mol) and IC50 (nM) oseltamivir, 
zanamivir and laninamivir 
 
 
Zanamivir Laninamivir Oseltamivir 
IC50* ABFE IC50* ABFE IC50* ABFE 
N1_closed 0.15 -8.1 0.28 -7.65 0.31 -8.58 
N1_N294S 0.48 -7.83 1.4 -8.32 28 -8.38 
N1_H274Y 1.5 -8.73 7.5 -8.85 1100 -7.72 
N9_closed 0.65 -7.97 0.74 -7.57 0.28 -8.87 
N9_R292K 35.68 -5.28 16.33 -5.59 2870 -5.16 
Correlation 0.959 0.659 0.986 
 
The IC50 was of zanamivir, laninamivir and oseltamivir for N1 and N9 
strains was collected from the work of Marjuki H et.al (Marjuki et al., 2014) and 
Yamashita (Yamashita, 2010)  respectively. Correlation was calculated between 
IC50 and average binding free energy obtained for zanamivir, laninamivir and 
oseltamivir. High correlation was obtained for oseltamivir and zanamivir i.e. 
0.986, 0.959 which dropped slightly for laninamivir i.e. 0.659 (Table 5.9).  
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Among the 10 PNI, IC50 for six inhibitors are reported for neuraminidase 
A i.e. N1_closed in our study. The correlation of 0.486 was observed between the 
documented IC50 and calculated average binding free energy (Table 5.10).  
 
Table 5.10  Correlation between IC50 and calculated binding free energy 
Compound IC50 (µg/ml) BFE 
ZINC13443833 
0.016 
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 Conformations of Glutamic276 in non-mutant strains 5.2.2
 
Comparison of the poses of N1_closed with oseltamivir, zanamivir and 
laninamivir (together all three will be referred as OZL) reveals that Glu276 can 
occupy two conformations suitable for both polar and non-polar interactions 
(Figure5.2). In the first conformation, i.e. with zanamivir and laninamivir as 
ligands, the carboxylic group faces the binding pocket thereby forming hydrogen 
bond with 8- and 9- hydroxyl of the glycerol group of zanamivir and laninamivir. 
On the other hand while oseltamivir is the ligand, carboxylic group of Glu276 
faces away from binding pocket thus making the pocket more hydrophobic in 
nature. This facilitates oseltamivir pentyloxy side to form non-polar interactions 
with Glu276. 
 Conformation of Glutamic276 leading to resistance 5.2.3
 
All three mutations, i.e. N294S, H274Y and R292K, results in movement 
of carboxylic group inside hydrophobic cavity with varying strength. This results 
in the disruption of hydrophobic cavity leading to resistance against oseltamivir.  
 N294S and H274Y mutations 5.2.3.1
 
Mutation of Asn294 to Ser294 (N294S) results in slight change in the 
position of Glu276 which has no effect on hydrogen bond formation with polar 
side chain of zanamivir or laninamivir (Figure5.3). The non-polar side chain of 
oseltamivir was pushed outside by about 1Å. The effect of Tyr347 being slightly 
flipped did not result in loss of hydrogen bond. However, the bond length of  





Figure5.1  Structures of oseltamivir, zanamivir, laninamivir and top 5 PNI accoring to ABFE 
 
Figure5.2 Conformation of Glu276 with osetlamivir, zanamivir and laninamivir as inhibitors 
 
Figure5.3 Comparsion of oseltamivir and zanamivir poses in N1_closed and N1_N294S. 




Figure5.4 Comparison of pose of oseltamivir, zanamivir in N1_closed and N1_H274Y. 
 
 
Figure5.5 Comparison of poses of oseltamivir, zanamivir in N9_closed and N9_R29K. 
 
 
Figure5.6 Comparsion of ZN88 and oseltamivr pose in N1_closed and N9_closed 
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hydrogen bond formed was higher by 0.2Å for mutated system. These results are 
in concordance with study performed by Collins et.al (Collins et al., 2009; Collins 
et al., 2008). 
As a result of H274Y, i.e. His274 to Tyr274, mutation, Glu276 moved 
inside the cavity by about 2Å thereby pushing the oseltamivir outside by about 
2.1Å (Figure5.4). However, the mutation resulted in orientation of Glu276 close 
to one required by zanamivir and laninamivir for formation of hydrogen bond. 
Hence, binding mode of zanamivir and laninamivir was not affected and they 
formed hydrogen bond with Glu276 in both closed and mutant strains. 
Effect of large inward movement of Glu276 in N1_H274Y as compared to 
N1_N294S was also evident by high binding free energy difference of oseltamivir 
between N1_H274Y and N1_closed in comparison to N1_N294S and N1_closed. 
 R292K mutation 5.2.3.2
 
The comparison of poses of oseltamivir in N9_closed and N9_R292K 
shows that mutation of Arg292 to Lys292 (R292K) causes the Glu276 to adopt a 
conformation enabling it to form salt bridge with Lys292 (Figure5.5). This 
inward movement disrupts the hydrophobic cavity required by oseltamivir’s 
pentyloxy group thereby shifting oseltamivir by 2.96Å which is in good 
agreement with a recent study (Yan Wu et al., 2013). The change in orientation of 
Glu276 has limited effect on zanamivir and laninamivir due to the formation of 
hydrogen bond between polar group of the side chain and Glu276. However, 
presence of Lys292 instead of Arg292 resulted in loss of hydrogen bond with the 
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carboxylic group of the ligand.  This causes resistance against OZL which is 
indicated by lowest binding free energy in N9_R292K. 
 Comparison of the poses of potential inhibitors with 5.2.4
wild strains 
 
 Comparison of the poses of ZN88 with oseltamivir in N1_closed and 
N9_closed (Figure5.6) indicates that side chain of ZN88 and oseltamivir are close 
to each other. In both N1_closed and N9_closed (Figure5.7) amino group of side 
chain of ZN88 forms salt-bridge with Glu276 and Glu277. Salt-bridge between 
amino group of side chain and Asp151 was observed in N1_closed. In addition, 
non-polar part of the side chain is involved in hydrophobic interactions.  
On the other hand, side chain of ZN33 shows more flexibility as observed 
from the poses with N1_closed and N9_closed (Figure5.7).  Similar to ZN33, the 
flexible side chain of ZN35 was found close to oseltamivir exploring the 
hydrophobic cavity in N1_closed and N9_closed (Figure5.9). In both ZN33 and 
ZN35, the ether group of the side chain was not able to form any hydrogen bond.  
The longer pentyl side chain of ZN21 was found to be close to the 
terminal of oseltamivir side chain in N1_closed. The side chain was found to be in 
different conformation in N1_closed thus indicating the flexibility of the side 
chain (Figure5.10). Despite of the presence of ketone group and amine group no 
polar interaction was observed. 
The side chain of ZN46 was found in close proximity to oseltamivir and 
formed non-polar interaction similar to other inhibitors (Figure5.11). In addition  




Figure5.7  Comparsion of the Interactions of ZN88 in N1_closed and N9_closed. 
 
Figure5.8 Comparsion of ZN33 and oseltamivr pose in N1_closed and N9_closed 
 
Figure5.9 Comparsion of ZN35 and oseltamivr pose in N1_closed and N9_closed.  




Figure5.10  Comparsion of ZN21 and oseltamivr pose in N1_closed and N9_closed 
 
 
Figure5.11 Comparsion of ZN46 and oseltamivr pose in N1_closed and N9_closed 
 
 
Figure5.12 Comparsion of the poses of ZN88 in different strains  
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the ketone group was also able to form additional hydrogen bond with Arg152. 
However, the amino group did not participate in hydrogen bond with Glu276, 
Glu277 and Asp151 like ZN88. 
Due to absence of side-chain amino group, ZN33, ZN35 and ZN21 lacked 
additional salt-bridge formed by ZN88. All inhibitors due to guanidino group 
formed hydrogen bond with Glu119, Asp151, Arg152, Trp178, Glu227 and 
between Arg152 and amide group similar to zanamivir and laninamivir. 
Increase of the side chain by one carbon in ZN35 in comparison to ZN33 
cause the shorter side chain to move inside the pocket. This indicates the side 
chain, only as long as propyl can occupy the binding cavity. The effect of longer 
chain was also observed in ZN21 where longer side chain hindered its entrance 
into the pocket. The unprotonated form of amino group in ZN46 resulted in 
absence of hydrogen bond with Glu276, Glu277 and Asp151. 
 Comparison of the poses of potential inhibitors with 5.2.5
mutant strains 
 
 The comparison of poses of ZN88 across different mutant strains reveals 
that pose with N1_N294S is almost similar to one with N1_closed (Figure5.12). 
However, for mutant N1_H274Y, where Glu276 is present more towards the 
pocket, the side chain of ZN88 is pushed backwards. In N9_R292K, the presence 
of Lys292 resulted in smaller hydrophobic cavity (Figure5.13a). It can be 
observed that side chain of pose in N1_H274Y crashes in the surface created by 
N9_R292K. This causes the side chain to rotate and still form the non-polar 
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interactions. In addition, the amino group of ZN88 was able to form salt-bridge 
with Glu276 in N9_R292K (Figure5.13b) and in N1_H274Y (Figure5.14). The 
interaction between Asp151 and ZN88 was not observed in N1_N294S 
(Figure5.14). 
Like ZN88, the pose of ZN33 in N1_closed was found similar to 
N1_N294S. However, for N1_H274Y the shorter ethyl side chain was found to be 
deep inside the cavity while propyl side chain was pushed outside (Figure5.15). 
For N9_R292K, the ethyl side chain was found inside the pocket while propyl 
was found facing outwards. The longer side chain was found to be shifted as a 
result of constricted hydrophobic cavity. The interactions with guanidine and 
amide group, similar to non-mutant strains, were found in all mutant systems. 
The effect of increase in length of the side chain can be observed from the 
orientations of ZN35. Except for N1_N294S, the side shorter chain was found 
inside the pocket for N1_closed and N1_H274Y. For N9_R292K the side chain 
was found to be twisted due to constrain in binding cavity (Figure5.16).  
Almost similar poses were observed for ZN21 in N1_closed, N1_N294S 
and N1_H274Y (Figure5.17). The side chain was found to be rotated in opposite 
direction in N9_R292K as compared to N9_closed. However, the effect of the 
change in hydrophobic cavity was not observed in both N9_closed and 
N9_R292K as the side chain was not found facing the base of the cavity. 
ZN46 was able to deal with the mutation by the change in orientation of side 
chain (Figure5.18). The vinyl group was able to form non-polar interaction with  
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a)                                     b) 
Figure5.13 a) Comparsion of the poses of ZN88 in N1_H274Y and N9_R292K b) Interaction of 
Zn88 in R292K 
 
 
Figure5.14 Comparsion of the poses of ZN88 in N1_N294S and N1_H274Y 
 
 
Figure5.15 Comparison of the poses of ZN33 in different strains 




Figure5.16 Comparison of the poses of ZN35 in different strains 
 
 
Figure5.17 Comparison of the poses of ZN21 in different strains 
 
 
Figure5.18 Comparison of the poses of ZN46 in different strain  
CHAPTER 5: NEURAMINIDASE RESULTS AND DISCUSSION                  95 
 
 
Tyr347 in N1_N294S and N1_H274Y; with Ala246 in N9_closed; and with 
Ile222 in N9_R292K. In addition, the ketone group was able to hydrogen bond 
with Arg152 in N1_closed and N9_R292K. 
For both ZN88 and ZN33 in N1_N294S and N1_closed, side chain was 
found close to each other due to less inwards movement of Glu276 inside 
hydrophobic cavity. On the other hand greater inward movement of Glu276 in 
N1_H274Y resulted in pushing side chains deeper in the pocket. ZN35, ZN21 and 
ZN46 indicate that the length of the side chain and the flexibility is a key 
determinant in formation of non-polar interactions. The presence of Lys292, in 
addition to inward movement of Glu276, caused the shift in side chain of ZN88 
and ZN33. Effect of constriction in hydrophobic cavity was also observed in 
ZN35 and ZN46. Nevertheless, all inhibitors were able to form non-polar 
interaction in all the systems.  
The central ring and guanidino group were unaffected by any mutation. 
Hence, interaction between Glu119, Asp151, Arg152, Trp178, Glu227, Arg152 
and guanidino group was still maintained similar to N1_closed and N9_closed. 
All inhibitors formed hydrogen bond with arginine triad i.e. Arg118, Arg292 and 
Arg371 in N1_closed except in N9_closed where Arg292 was replaced with 
Lys292. 
In addition, ZN88 was able to form hydrogen bond with Glu276 and 
Glu277 in all the cases. Though hydrogen bond was not observed between 
Asp151 and side chain of ZN88, the distance was close enough to make 
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interactions. It is possible that a slight change in conformation might lead to 
formation of hydrogen bond. The concluding remarks of this work have been 
described in Chapter 9. 
 
 






This chapter describes one of the most important biological processes 
known as apoptosis and its role in maintaining cell balance (6.1). It also 
describes the control of apoptosis by BCL-2 family of proteins and implications in 
cancer (6.2). Importance of Myeloid cell leukemia-1 (MCL-1) in apoptosis and as 
a drug target is discussed in 6.3 section. 
 
 Apoptosis  6.1
 
The study by Kerr et.al. (Kerr, Wyllie, & Currie, 1972) highlighted the 
importance of a process known as cell death or apoptosis. According to them, 
apoptosis plays a complementary and opposite role to mitosis, thereby regulating 
cell population. In multicellular organisms, the delicate balance between the 
number of cells to be eliminated and number of new cells produced is maintained 
by apoptosis (Meier, Finch, & Evan, 2000).  Apoptosis is activated whenever 
tissue modeling is required and has many essential roles (Golstein, 1998) such as 
it eliminates the less fit cells in vertebrate epiblast (Claveria, Giovinazzo, Sierra, 
& Torres, 2013), shapes the embryo (e.g. by removing interdigital cells during 
limb formation) (Zuzarte-Luis & Hurle, 2002), eliminates autoreactive and non-
functioning immature lymphocytes (Rathmell & Thompson, 2002).   
CHAPTER 6: MCL-1                                                                                          98 
 
 
 Apoptosis and Cancer 6.1.1
 
In a seminal study, Weinberg and Hanahan (Hanahan & Weinberg, 2000) 
described six hallmarks traits that govern the transformation of normal cells to 
cancer cells. They include sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis. Recently, this list  
was updated to include four more traits i.e., genome instability and mutation, 
tumor-promoting inflammation, avoiding immune destruction and deregulating 
cellular energetics (Hanahan & Weinberg, 2011). Among all these, apoptosis has 
been the center of attraction as cancer cells try to evade cell death either by 
inactivation of pro-apoptotic or up-regulation of anti-apoptotic factors (Marsoni & 
Damia, 2004). 
 Apoptotic Pathways 6.1.2
 
Apoptosis involves the following steps: detection of stress signals, 
suppression of anti-apoptotic proteins, activation of pro-apoptotic proteins, release 
of apoptosis inducing agents from mitochondria inter-membrane space (IMS) 
such as cytochrome c and Smac/DIABLO, activation of caspases and finally cell 
death (Tait & Green, 2010). Caspases are effector molecules in apoptotic pathwa- 
  




Figure6.1 The intrinsic and extrinsic apoptotic pathways (adapted from (Peter E. Czabotar, 
Lessene, Strasser, & Adams, 2014; Youle & Strasser, 2008)). 
Cytotoxic stimulus like intracellular damage, cytokine deprivation initiates the intrinsic pathway 
by activation of BH3-only proteins. BH3 proteins inhibit anti-apoptotic BCL-2 proteins thus 
indirectly activating apototic proteins BAX and BAK. However, Some BH3-only proteins, such as 
BIM and PUMA, may also be able to directly activate BAX or BAK. BAX and BAK after 
oligomerization cause mitochondrial outer membrane permeabilization (MOMP) thereby releasing 
cytochrome C (Cyt C) and SMAC. Cytochrome C combines with APAF1 to form apoptosome 
which in turn activates pro-caspase 9 to caspase 9. SMAC inhibits XIAP (X-linked inhibitor of 
apoptosis protein) which can inhibit caspase 9. Caspase 9 activates effector caspases e.g. caspase 
3, caspase 7 causing cell death. Extrinsic pathway is activated by various factors such as genotoxic 
agents. Death receptor on activation recruits protein with a death domain (DD) which in turn 
recruits pro-caspase 8 leading to its activation. Caspase 8 creates active form of BID i.e. tBID by 
cleavage. tBID links extrinsic pathway to intrinsic pathway.  




Figure6.2 Classification of core B-cell lymphoma-2 (BCL-2) family proteins on the basis of 
BCL-2 homology (BH) domains (adapted from (L. W. Thomas, Lam, & Edwards, 2010)) 
 
Figure6.3 The selective interactions within BCL-2 family members. (adapted from (Peter E. 
Czabotar et al., 2014)) 
 a) It can be observed that promiscuous binders BIM, PUMA and tBID can inhibit all the anti-
apoptotic proteins. On the other hand, NOXA interact only with MCL-1 and A1 and BAD only 
with BCL-2, BCL-XL and BCL-W and are known as selective binders b) Similarly BAX can be 
inhibited by all anti-apoptotic members while BAK is only inhibited by BCL-XL, MCL-1 and A1  
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-ys and are synthesized as inactive pro-caspases. On initiation of apoptotic 
pathway, these pro-caspases convert to active form via cleavage of a pro-domain 
mostly by other caspases (Favaloro, Allocati, Graziano, Di Ilio, & De Laurenzi, 
2012). Caspases can be activated by two major pathways (Figure6.1) i.e. extrinsic 
pathway and intrinsic pathway (Fulda & Debatin, 2006). 
 BCL-2 Protein Family 6.2
 
BCL-2 was discovered over 20 years ago as a result of its upregulation in 
follicular B-cell lymphoma. This was a milestone discovery as overexpression of 
BCL-2 inhibited the cell death instead of promoting cell proliferation like most 
previously discovered oncogenes (Tsujimoto, Ikegaki, & Croce, 1987). It has 
been widely accepted that BCL-2 family of proteins, is essential for the 
development and maintenance of homeostasis. 
BCL-2 family proteins are characterized by the presence of four regions of 
sequence homology i.e. BCL-2 homology (BH) domains. Based on structural and 
functional features, BCL-2 proteins family can be divided into three sub-families 
i.e. anti-apoptotic proteins, multi-domain pro-apoptotic proteins (also known as 
effector proteins) and BH3-only pro-apoptotic proteins (Figure6.2). The anti-
apoptotic proteins includes BCL-2, BCL-XL, MCL-1, BCL-W and BCL‑2A1; 
effector proteins consists of  BAX, BAK and BOK; and BH3-only pro-apoptotic 
proteins comprise of BIM, BID, PUMA, BAD, HRK, NOXA and BMF. 
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 BCL-2 family protein-protein interactions  6.2.1
 
The BH3-only proteins act upstream of BAX and BAK which can be 
deduced from the fact that in the absence of BAX and BAK, BH3-only proteins 
cannot induce apoptosis on their own. Initially, it was believed that activated 
BH3-only proteins can bind to all pro-survival counterparts. However, due to 
subtle differences in their BH3 domains and in the groves of the anti-apoptotic 
proteins, it was found that different BH3-only proteins have varying affinity 
towards anti-apoptotic counterparts (Figure6.3). BIM, PUMA and tBID can bind 
to all the pro-survival proteins and are knows as promiscuous binders. On the 
other hand, NOXA interact only with Mcl-1 and A1 and BAD only with BCL2, 
BCL-XL and BCL-W and are known as selective binders (Weyhenmeyer, 
Murphy, Prehn, & Murphy, 2012). 
 BCL-2 family proteins as therapeutic targets 6.2.2
BCL-2 family members have essential roles right from early 
embryogenesis to adult tissue homeostasis. BCL-2 family of proteins regulates 
apoptosis which is important for embryonic development and prevention of 
cancer. In addition to apoptosis, Bcl-2-family proteins regulate other types of cell 
death, including necrosis and autophagy, thus acting as nodal points where 
multiple pathways converge (Yip & Reed, 2008). BCL-2 proteins also play 
critical roles in non-cancerous cells by maintaining neuronal activity, autophagy, 
calcium handling, mitochondrial dynamics and energetics (Hardwick & Soane, 
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2013). Some of the important effects caused by their deletion can be seen in 
Table 6.1 (Peter E. Czabotar et al., 2014; Youle & Strasser, 2008) 
 






Abnormal death of renal epithelial progenitors, death of mature B and T 
lymphocytes causing defective immune system, premature greying  
BCL-XL 
Death of fetal erythroid progenitors and neuronal cells. Loss of a single allele 
encoding BCL‑XL decreases spermatogenesis and reduces platelet numbers, 
while loss of both alleles kills hepatocytes resulting in liver fibrosis  
BCL-W Death of developing sperm cell leading to male sterility  
A1 Death of granulocytes and mast cells  
MCL1 
Loss of MCL1 causes failure in implantation, premature death of B and T 
lymphoid cells, cardiomyopathy and heart failure  
Effector Proteins 
BAX Mild lymphoid hyperplasia, male sterility  
BAK 






Lymphoid and myeloid cell hyperplasia, SLE-like autoimmune disease, 
abnormal resistance to cytokine deprivation, deregulated calcium flux  
BID Resistance to hepatocyte killing, fatal hepatitis  
PUMA Resistant to DNA damage, cytokine deprivation and glucocorticoids  
BAD Resistance to loss of epidermal growth factor or insulin growth factor  
HRK Mild resistance to deprivation of nerve growth factor  
BIK No defects till date  
NOXA 
Mild resistance of fibroblasts to γ-irradiation , but high resistance of 
fibroblasts and keratinocytes in the skin to UV radiation  
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Any flaw in the apoptotic pathway causes several diseases, particularly 
cancer and autoimmunity.  Inhibition of apoptotic pathway not only causes tumor 
progression but also leads to resistance of diverse tumours against chemotoxic 
drugs (Peter E. Czabotar et al., 2014). On the other hand too much apoptosis can 
enhance ischaemic conditions leading to neurodegeneration (Peter E. Czabotar et 
al., 2014). 
 BH3 mimetic as potential drugs 6.2.3
  
Targeting the regulation of anti-apoptotic BCL‑2 family members is the 
most attractive approach. Most of the tumors show increased levels of BH3-only 
proteins due to high levels of anti-apoptotic proteins. Such findings along with the 
success of stapled BH peptides have resulted in the search for BH3 mimetics. 
However, the long, shallow and mainly hydrophobic grove of the anti-apoptotic 
BCL-2 proteins is more challenging and thus only a few slightly potent MCL1 
inhibitors have been discovered. Several small-molecule BH3 mimetics have been 
identified but most of them bind their targets with moderate affinity (Peter E. 
Czabotar et al., 2014; Juin, Geneste, Gautier, Depil, & Campone, 2013). 
Following the line of BH3 mimetics, two potential drugs ABT-737, a BH3 
mimetic modeled after BH3 domain of BAD (Oltersdorf et al., 2005), and ABT-
263 (Tse, 2008) have been launched (Figure6.4). Both ABT-737 and ABT-263 
bind strongly to BCL-2, BCL-XL and BCL-W but not to MCL-1 (Lee et al., 
2007; Oltersdorf et al., 2005). Surprisingly the target of these drugs is BIM-BCL-
2 complex instead of unoccupied BCL-2. Furthermore, their affinity towards 
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BIM-BCL-2 complexes is much more than BIM-BCL-XL or BIM-BCL-W 
complexes (Merino et al., 2012). Thus, increased level of BCL-XL, MCL-1 or A1 
can lead to the resistance against ABT-737 and ABT-263.  Moreover, the ability 
of ABT-263 to act on BCL-XL causes toxicity due to role of BCL-XL in 
controlling the platelet lifespan (Roberts et al., 2012). These findings indicate that 
BH3 mimetics targeting single anti-apoptotic proteins might be better approach. 
The selective target approach was applied in ABT-199, which is a selective BCL-
2 inhibitor. 
 





 MCL-1 as a drug target 6.2.4
 
MCL-1 is among the most frequently amplified genes in human cancer (G. 
Wei et al., 2012) and has been linked to several cancer including lung, breast, 
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prostate, pancreatic, ovarian, melanoma, leukemia and cervical cancers, making it 
an appealing target (Akgul, 2009; Brotin et al., 2010; Cavarretta et al., 2006; Ding 
et al., 2007; Goncharenko-Khaider, Matte, Lane, Rancourt, & Piche, 2012; Gores 
& Kaufmann, 2012; Mitchell et al., 2010; L. Song, Coppola, Livingston, Cress, & 
Haura, 2005; H. Zhang et al., 2011; Zhou et al., 2013). Moreover, MCL-1 
overexpression has emerged as a resistance mechanism against a number of 
anticancer drugs such as ABT-263 (Tse, 2008), ABT-737 (Yecies, Carlson, Deng, 
& Letai, 2010), BT-199 (Souers et al., 2013) and WEHI-539, as well against 
gemcitabine (S. H. Wei et al., 2008), the widely prescribed drug for pancreatic 
cancer (Lessene, 2013). Though the crucial physiological role of MCL1 suggests 
that targeting it might produce severe side effects, many cancers like acute 
myeloid leukaemia cells are more sensitive to the loss of MCL1. Hence, there is 
need of MCL-1 inhibitors with a well-defined therapeutic window. 
  MCL-1 6.3
 
The human MCL-1 gene is located on chromosome 1q21 and consists of 
three exons. As a result of alternative splicing, MCL-1 gene translate into two 
isoforms i.e. MCL-1L and MCL-1S. MCL-1L (or generally called as MCL-1) 
unlike other anti-apoptotic members possess three BH domains (Figure6.2) i.e. 
BH1-BH3 and lacks BH4 domain (Akgul, 2009).  MCL-1 contains two PEST 
sequences i.e. sequences containing mainly of proline (P), glutamic acid (E), 
serine (S) and threonine (T) at N-terminal (Le Gouill, Podar, Harousseau, & 
Anderson, 2004). These PEST sequences are characteristic of MCL-1 and respon- 






                                                                         b) 
Figure6.5 Structure of MCL-1 
a) Structure of MCL-1 revealing the hydrophobic grove formed by α2-4 and α8 helices with α5 
forming core of the hydrophobic grove. The pockets P1- P4 are defined by residues 2d, 3a, 3d and 
4a respectively of BIM-BH-3 only protein. b) It can be observed that pocket P2 is deepest among 
all the pockets and pocket P4 is separated from the rest three pockets by a saddle like intervention 
with which Gly266 is aligned. The hydrophobic grove is flanked by electropositive residues 
shown by blue colour of the surface. 
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-sible for its short half-life (Akgul, 2009). Similar to other anti-apoptotic 
members, MCL-1 contains C-terminal transmembrane domain that helps to insert 
into different intracellular membranes including mitochondria (Michels, Johnson, 
& Packham, 2005). MCL-1 is localized at intracellular membranes including 
mitochondria as well as in cytoplasm. Localization of MCL-1 at outer 
mitochondrial membrane is important for its anti-apoptotic function. MCL-1 
localized at mitochondrial membrane inhibits apoptosis by forming dimer with 
pro-apoptotic member BAK thereby suppressing cytochrome-c release from 
mitochondria (Akgul, 2009).  
 MCL-1 function 6.3.1
 
In vitro studies indicate that similar to other anti-apoptotic members, 
MCL-1 sequesters BAK, thereby preventing its oligomerization. This interaction 
is disrupted by NOXA, BIM, BID and PUMA causing cell death (M. R. Warr & 
Shore, 2008). Different BH3-only proteins have different effect upon binding with 
MCL-1. It has been shown that BIM and PUMA stabilizes MCL-1 while NOXA 
induces proteasomal-dependent MCL-1 degradation (P. E. Czabotar et al., 2007).  
 MCL-1 versus BCL-2 family member’s specificity 6.3.2
 
The topology of MCL-1 is similar to other BCL-2 family member 
proteins. MCL-1 is composed of eight helices i.e. α1 (residues 172-191), α2 
(residues 204-221), α3 (residues 225-235), α4 (residues 244-256), α5 (residues 
261-281), α6 (residues 288-301), α7 (residues 303-308) and α8 (residues 312-
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318) where central hydrophobic α5 helix is enveloped by rest seven helices. 
However, the grove is composed of α2-4 and α8 helices surrounding α5 helix 
which forms core of grove (Figure6.4a). Despite the fact that MCL-1 has similar 
structure, it has a distinct BH3 binding profile (Figure6.3).  
Although MCL-1 has a very similar structure with other anti-apoptotic 
BCL-2 proteins, having less than 2Å backbone root mean square deviation 
(RMSD) over conserved helices, it only shares ~25% sequence identity (Day et 
al., 2005; Fire, Gullá, Grant, & Keating, 2010).  Comparison of MCL-1 and BCL-
XL reveals that α3 helix is longer in MCL-1. MCL-1 surface is electropositive in 
nature due to fourteen lysine and four histidine residues present at α3, α3-α4 loop, 
and α4 while BCL-XL grove is essentially uncharged (Figure6.4b). Moreover, 
the binding grove in BCL-XL is tightly packed due to hydrogen bond between 
Gln111 of α3 and Glu129 of α4 in comparison to Lys215 and His233 in MCL-1. 
This results in significantly different BH3 binding profile of MCL-1 in 
comparison to other anti-apoptotic members (Day et al., 2005; Quinn et al., 2011).  
 BH3 and interaction with MCL-1 6.3.3
 
The sequences of BH3 peptides are highly variable. However, for all BH3 
the residues follow a heptad repeat, [abcdefg]n, with ‘‘a’’ and ‘‘d’’ positions 
buried in the hydrophobic pocket of the respective partner. It has been observed 
that residues at position 3e (mostly having small residue like glycine), aspartic 
acid at 3f and four hydrophobic residues at positions 2d, 3a, 3d and 4a (4a means 
residues at a position in 4th heptad repeat) are more or less conserved.  The 
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pockets corresponding to the four hydrophobic residues 2d, 3a, 3d and 4a in anti-
apoptotic members are known as P1, P2, P3 and P4 respectively (Figure6.4a).  
The difference in residues at positions 2d, 3a, 3d and 4a can lead to 
difference in specificity (Fire et al., 2010). In BH3-only proteins, 2d  is the least 
conserved of all four hydrophobic residues i.e. 2d, 3a, 3d and 4a while the 
hydrophobic residues 3a and 3d are highly conserved.  Though residues 3a and 3d 
provide stability but their role in selectivity is yet not clear (Day et al., 2005). 
As can be seen from Figure6.4b the pockets are of varying depths and 
sizes. The P2 pocket is the deepest among them and is contiguous with the 
shallower pockets P1 and P3. Residue 3e aligns with a saddle point which 
separates the pocket P1, P2 and P3 from P4. Structure compounds targeting BCL‑
2, BCL‑XL or MCL-1 reveals that all compounds are anchored in the P2 
hydrophobic pocket. The P2 pocket appears to be critical for binding all of the 
ligands because of its plasticity and ability to accommodate the BH3 mimetics 
into deep cavities not present with natural ligands (P. E. Czabotar et al., 2007). 
The important role of the conserved residues 2d, 3a, 3d, 4a and 3g are as follows: 
  Position 2d 6.3.3.1
 
 The binding pocket P1 surrounding 2d is formed by residues of α3 and α4 
helices i.e. Met231, Lys234, Leu235, Val249 and Phe270. Moreover, it seems that 
the interaction with pocket P1 forms the selctive binding criteria (Day et al., 
2005). 
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 MCL-1 can undergo local conformational change at the 2d position to 
accommodate isoleucine, smaller residue alanine or even larger residues like 
tyrosine. In case of smaller residue alanine Leu235 shifts to fill the cavity. While 
for large residue like tyrosine, a more prominent movement of α3 region of MCL-
1 by 1.7 Å away from the peptide and 1.2 Å movement of peptide away from 
MCL-1 is observed. This movement is facilitated by the local conformational 
changes in peptide and α3 helix of MCL-1. (Fire et al., 2010).  
 Position 3a 6.3.3.2
 
Pocket P2, engaged by 3a, is formed by Met231, Val249, Val253, Leu267, 
Phe270 in case of MCL-1. This pocket cannot accommodate charged or polar 
residues (Fire et al., 2010). 
 Positions 3d 6.3.3.3
 
Residues Val220, His224, Ala227, Phe228, Met231 and Thr266 forms 
pocket P3 enveloping 3d. Due to less helical α3/α2 region of the receptor, 3d site 
is less tightly packed in BCL-XL in comparison to MCL-1. In MCL-1, the site is 
constrained to isoleucine whereas BCL-XL can accommodate a range of residues. 
(Dutta et al., 2010; Fire et al., 2010).  
 Position 4a 6.3.3.4
 
  The pocket P4 formed by Val216, Val220, Val265, Phe319 for MCL-1 is 
found to be more open and solvent exposed in MCL-1 as compared to BCL-XL. 
This makes MCL-1 tolerant to many mutations at site 4a while BCL-XL is more 
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constrained at this site. If 4a site is replaced with charged or polar amino acids, 
affinity of the BH3 only protein to BCL-XL drops significantly (Fire et al., 2010).  
 Positions 3g 6.3.3.5
 
 Presence of negatively charged residues at 3g position makes BH3 only 
proteins BCL-XL specific due to presence of arginine. On the other hand, NOXA, 
a MCL-1 specific BH3-only protein, has a lysine at this position. Mutation of 
lysine to glutamic acid increases the affinity of NOXA towards BCL-XL (Fire et 
al., 2010). 
Comparison of apo and holo forms of both BCL-XL and MCL-1 reveals 
that binding grove needs to open in order to accommodate BIM BH3 peptide. The 
structural change accompanied with binding grove opening is largest in P2 and P3 
(P. E. Czabotar et al., 2007). While, MCL-1 achieves it by reorientation of 
carboxy-terminal end of α4 helix, BCL-XL does it by shifting the residues that 
compose α3 helix (Fire et al., 2010). This can be attributed to the higher flexibility 
of α4 helix in MCL-1 and α3 helix in BCL-XL (C.-Y. Yang & Wang, 2012). 
 Targeting MCL-1 6.3.4
 
Numerous approaches have been applied to target MCL-1. However, most 
of them are not MCL-1 specific and target multiple anti-apoptotic proteins. BH3 
mimetic is one of the most promising approaches and has been applied to discover 
some of the recent drugs.  





It is one of the most successful BH3 mimetic and has strong affinity 
towards anti-apoptotic members of the BCL-2 family. The chloro-biphenyl 
moiety and thio-phenyl moiety of ABT-737 occupies P2 and P4 pocket 
respectively. MCL-1 and BCL-XL differs in P2 pocket. Moreover, in MCL-1, P4 
pocket is relatively more open and exposed towards the solvent. Hence, ABT-737 
does not bind with MCL-1, thereby fails in cancer with overexpression of MCL-1 
(Lee et al., 2007). 






The methods used to explain the activity of the compounds against MCL-1 
are elaborated in this chapter. Docking and molecular dynamics are explained in 
7.1 and 7.2 sections respectively. The specific parameters for MCL-1 are also 




 Structure preparation 7.1.1
 
 The structure of MCL-1 (PDB id 2NL9) was downloaded from PDB. 
Ligand and water molecules were deleted from PDB structure and the resulting 
structure was prepared using MOE. The structure was prepared by addition of 
hydrogen atoms, structure correction, protonation states according to pH 7 and 
energy minimization of hydrogen atoms keeping heavy atoms fixed. The 
calculation of partial charges and energy minimization was performed using 
AMBER99 within MOE.  
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 Active site 7.1.2
 
 Active site was determined by selecting the residues within 6Å of the 
natural peptide. It comprised of Arg215, Val216, Gly217, Gly219, Val220, 
His224, Ala227, Phe228, Gly230, Met231, Leu232, Lys234, Leu235, Asp236, 
Lys244, Ser245, Leu246, Arg248, Val249, Met250, His252, Val253, Phe254, 
Ser255, Asp256, Gly257, Val258, Asn260, Trp261, Gly262, Arg263, Ile264, 
Val265, Thr266, Leu267, Phe270, Phe318, Phe319, His320 and Val231. 
 Dataset for docking 7.1.3
 
In the study by Bernando et al.  (Bernardo et al., 2010), compounds having 
rhodanine scaffold, i.e. ST_1_046 and ST_1_109 Table7.1, were reported to be 
active against MCL-1. ST_1_046 and ST_1_109 exhibited different pro-survival 
protein selectivity. While ST_1_046 acted as selective Mcl-1 inhibitor, ST_1_109 
showed activity against both Mcl-1 and Bcl-XL. The selectivity of ST_1_046 
towards Mcl-1 was credited to the para-methoxy group, which fits perfectly in the 
binding groove of Mcl-1 but faces steric repulsion in the binding groove of Bcl-
XL. In the work by Bernardo et al., effect of substituent groups towards 
selectivity and activity was studied but function of the rhodanine scaffold was not 
understood. Rhodanine-based compounds are known as pan assay interference 
compounds (PAINS) due to frequent hits in screening campaigns. Rhodanine-
based compounds can non-specifically interact with proteins in multiple ways due 
to more than one reactive site present on rhodanine. Thus activity of compounds 
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possessing a rhodanine moiety is considered very skeptically despite convincing 
results (Tomasic & Peterlin Masic, 2012). 
To understand the functional role of the scaffold in interaction with anti-
apoptotic proteins, our collaborator Miss Tang Shi Qing graduate student Dr. 
Christina CHAI, used scaffold-hopping strategy to swap the rhodanine scaffold 
with structurally related five-membered multihetrocyclic rings, i.e. 
thiohydantoins, hydantoins and thiazolidinediones Table7.1 were used for 
docking. These rings differ in the presence of the exocyclic and endocyclic sulfur 
atoms. The compounds synthesized have biaryl substituents similar to ST_1_046 
and ST_1_109 for direct comparison. In addition to similar biarayl substituents, 
bicyclic methylidene substituent and naphthalene-1-yl methylene was also 
synthesized to analyze the effect of multicyclic arylidenes versus biaryl arylidenes 
in the different heterocyclic systems. 
 Fluorescence polarization assay 7.1.3.1
 
The inhibitory activity of the compounds against Mcl-1 and Bcl-XL was 
evaluated with fluorescence polarization assay (FPA) by our collaborator Miss 
Tang Shi Qing graduate student Dr. Christina CHAI. FPA was performed by 
using a fluorescein tagged BH3 domain of Bak peptide as the fluorescent source. 
The Bak peptide was chosen because it is known to bind to both proteins of 
interest. The optimal protein concentration to be used for the assay was firstly 
determined via a protein titration with 60 nM of Flu-Bak ligand. From the titration 
curves, the optimal protein concentration for Mcl-1 and Bcl-XL were found to be  
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63.75 μg/ml and 37.5 μg/ml respectively. Using the optimal protein concentration, 
the IC50 values of our compounds were obtained by performing a 10-point 2-fold 
dilution of the compounds with 60 nM of Flu-Bak and 63.75 μg/ml and 35.60 
μg/ml Mcl-1 and Bcl-XL respectively. All the IC50 values determinations were 
carried out in triplicates and average IC50 was reported Table7.1 
 Molecular Docking 7.1.4
 
Docking was performed in MOE by default parameters. Primary challenge 
in a docking study is prediction of the correct binding pose. The involvement of 
rhodanine moiety enhanced this problem thus post-processing of the docking 
results was performed. Different methods for post-processing of the docking 
results such as using MPBSA (Lindstrom et al., 2011) clustering (Kozakov, 
Clodfelter, Vajda, & Camacho, 2005) and short MD simulation have been applied 
(Yuriev & Ramsland, 2013). In our work poses predicted by MOE were clustered 
and the pose with best docking score of highest cluster was selected for further 
analysis.  
 Molecular Dynamics 7.2
 
 System preparation 7.2.1
 
For molecular dynamics structure with PDB id 4HW4 was used which has 
complete human sequence as compared to 2NL9. The best pose predicted by 
docking was overlapped with 4HW4 and was used as starting structure. The 
partial charges and force field parameters for the compounds were generated 
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automatically by the antechamber suite in AMBER12 (D.A. Case, 2012). The 
general AMBER force field (gaff) (J. Wang et al., 2004) was used for the 
compounds, and AMBER ff12SB force field for the proteins. All missing 
hydrogen atoms of the proteins were added using the LEaP module in AMBER12. 
Systems were solvated using TIP3P (Jorgensen et al., 1983) water in a octahedron 
box extending 12 Å beyond any solute atom. The system was made neutral by 
adding appropriate number of counter ions.  
 Minimization, heating up and equilibration of system 7.2.2
 
Molecular dynamics simulations were performed using pmemd.cuda in 
AMBER12. Water molecules and counter ions were minimized with 500 cycles of 
steepest descent followed by same number of conjugate gradient cycles. This was 
followed by energy minimization of the entire system. Molecular dynamics 
simulations were performed using a time step of 2 fs with a cutoff radius of 8Å 
for the non-bonded interactions. Long range electrostatic interactions were 
calculated by particle-mesh Ewald (PME) method (Darden, York, & Pedersen, 
1993). The bonds involving hydrogen were constrained using SHAKE algorithm 
(Ryckaert, Ciccotti, & Berendsen, 1977) and Langevin dynamics was used for 
temperature control. The temperature was gradually increased from 0k to 310K 
with protein restraints over a period of 20ps at NVT conditions. This was 
followed by 1000ps of NPT equilibration at 1 atm pressure and later succeeded by 
production run. The periodic boundary conditions (PBC) were used during 
molecular dynamics simulations. 
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 Production run 7.2.3
 
It has been suggested that single longer trajectory approach does not 
necessarily lead to good results (T. Hou, J. Wang, Y. Li, & W. Wang, 2011). 
Moreover, in a recent study it was shown that a single run samples the system 
inadequately and replicate trajectories enhances the search of conformational 
space (Adler & Beroza, 2013) . Coordinates of not more than 1% of the atoms of 
the receptor was altered by 0.001 Å while keeping the initial velocities unchanged 
of the equilibrated systems. The production run was performed on these modified 
coordinates to generate five replicate trajectories of 10ns each. However, 
considering the flexibility of the α4 helix, comprising key residues forming P1 
and P2 pocket, a single longer simulation of 50ns was also generated.  
The RMSD of the backbone atoms was calculated for the trajectories. 
Depending on the analysis the later 5ns of each replicate trajectory was merged 
into a single trajectory of 25 ns for further analysis. Similarly first 5ns of the 
trajectory was discarded for longer 50ns trajectory. However, this single longer 
trajectory 45ns (will be referred to as 45NsT from now on) was not merged with 
shorter 25ns one (will be referred to as 25NsT from now on) to avoid bias for one 
particular pose. The clustering analysis was performed for the both 25NsT and 
45NsT by cpptraj of AMBER12.  
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 Binding free energy 7.2.4
  
The binding free energy for each system was calculated by the MM/GBSA 
approach. MM/GBSA was selected as it has been shown in many recent studies 
that MM/GBSA produces results with comparable accuracy to MM/PBSA and 
outperforms its counterpart while calculating relative binding free energies at less 
computational cost (Tingjun Hou, Junmei Wang, Youyong Li, & Wei Wang, 
2011; Srivastava & Sastry, 2012).  MMGBSA approach combines molecular 
mechanical energies with the continuum solvent approaches using sander program 
from Amber12. The binding free energy (ΔGbind) of the compounds in each 
complex was calculated according ΔGbind = Gcomplex - Gprotein - Gligand = ΔH + 
ΔGsolvation – TΔS = ΔEMM + ΔGGB + ΔGSA – TΔS (1 where ΔEMM is the gas-phase 
interaction energy between protein and ligand, including the electrostatic and Van 
der Waals interactions; ΔGGB and ΔGSA are the polar and non-polar components 
of the desolvation free energy and TΔS is the change of the conformational 
entropy upon ligand binding. 
ΔGbind = Gcomplex - Gprotein - Gligand = ΔH + ΔGsolvation – TΔS = ΔEMM + ΔGGB + ΔGSA – TΔS (1) 
 The gas phase free energy contributions are calculated by sander within 
the Amber program suite. The solvation free energy contributions can be further 
decomposed into an electrostatic and hydrophobic contribution. The electrostatic 
portion was calculated using Generalized Born (GB) method with igb = 2 
(Onufriev, Bashford, & Case, 2000, 2004), with salt concentration 0.1 Molarity 
and PM3 semi-empirical Hamiltonian used for the quantum calculation. The 
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hydrophobic contribution is approximated by the LCPO method (Weiser, 
Shenkin, & Still, 1999) implemented within sander. 




MCL-1 Results and Discussion 
 
The results of the docking and molecular dynamics study to explain 
activity against MCL-1 are explained in this chapter.  The results of the clustering 
and analysis of the subsequent poses are discussed. 
 
 MCL-1 versus BCL-XL 8.1
 
As a result of overlapping residues it was observed that residues such as 
Ala93, Glu96, Phe97, Arg100, Tyr101, Leu112, Ser122, Gln125, Val126, 
Leu130, Gly138, Arg139, Ala142, Phe143, Phe146 and Tyr196, that are part of 
binding pocket or close to it are more pronounced in BCL-XL. More than other 
residues, Phe146 and Phe97 seem to be having more effect by reducing depth of 
P2 and P3 cavity respectively. The P2 cavity was observed to be distinguishing 
feature as it seems to be deeper than BCL-XL. 
 Docking  8.2
The poses of the compounds indicated that the active compounds utilize 
the P2 pocket. However, the results could not explain the reason why certain 
compounds were strongly active while others were not.    
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 Molecular Dynamics 8.3
 
The trajectories for most of the simulations were found to be equilibrated 




Clustering analysis performed on 25NsT (Table 8.1) shows that for 
ST_1_159, ST_1_261 there was no consensus and ligand occupied different 
orientations. Moreover, difference in size of first and second cluster ST_1_227 
and ST_1_249 was not too large. The representative poses from both first and 
second cluster was considered for analysis of these compounds. For the remaining 
compounds, their representative pose from top cluster was selected for analysis. 
 
Table 8.1 The cluster size of top three clusters is shown. 
 
Compounds* Cluster_1 Cluster_2 Cluster_3 
ST_1_109 1715 500 285 
ST_1_159 1098 1000 397 
ST_1_162 2000 440 60 
ST_1_208 1500 500 471 
ST_1_202 2500   
ST_1_222 1680 351 244 
ST_1_227 838 500 361 
ST_1_247 2499   
ST_1_249 1224 979 217 
ST_1_261 500 500 500 
ST_1_046 1653 500 347 
ST_1_R1N 2500   
              *2500 can be the highest number of poses possible 
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 Binding free energy calculation 8.3.2
 
Table 8.2 shows the average binding free energy (Avg_GBSA) calculated 
from 5 trajectories, which has a Pearson correlation coefficient of 0.2693 with 
IC50. However, after discarding values >100 from calculation value of the Pearson 
correlation coefficient increased to 0.655. Avg_GBSA was not able to clearly 
rank the compounds according to activity, as ST_1_046 was ranked third 
according to Avg_GBSA (Avg) even though it is the strongest inhibitor. 
 



















ST_1_109 -31.8544 -31.1679 -23.6406 -30.6913 -32.0964 -29.8901 22.31 
R1N -29.7772 -28.3109 -30.349 -28.7014 -27.5232 -28.9323 17.84 
ST_1_046 -27.7594 -29.812 -30.0837 -27.0106 -29.8793 -28.909 10.64 
ST_1_202 -27.8631 -26.548 -27.0877 -27.3295 -27.0592 -27.1775 58.5 
ST_1_222 -22.8788 -28.9803 -30.9283 -23.6671 -27.8489 -26.8607 57.68 
ST_1_247 -28.5871 -26.5147 -25.968 -25.4701 -27.1897 -26.7459 38.46 
St_1_159 -25.1196 -23.1986 -26.5482 -27.881 -24.0857 -25.3666 100 
ST_1_162 -16.9434 -26.4017 -28.1194 -27.177 -27.8438 -25.2971 100 
ST_1_249 -28.1785 -24.4087 -28.2246 -22.3472 -19.6618 -24.5642 100 
ST_1_208 -18.313 -24.0395 -25.2114 -23.5915 -28.7542 -23.9819 38.97 
ST_1_227 -23.0639 -24.9602 -29.8268 -27.8299 -12.1799 -23.5721 45.9 






Clustering of pose for 25NsT reveals that ST_1_046 occupies P1, P2 and 
P3 pocket of the MCL-1 binding grove (Figure8.3). The 3,4 dimethoxy group 
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faces the base of the P1 cavity and forms van der Waals interaction with Leu246 
and Val249, while phenyl ring forms π-π and π-alkyl interactions with Met231 
and Phe270. Pyridine ring forms π-interactions with Val253 and Met231. In 
addition, Arg263 is involved in formation of salt bridge with carboxylic group 
and Van der Waal’s interaction with exocyclic oxygen present in rhodanine ring. 
Exocyclic oxygen is involved in formation of Van der Waal’s interaction with 
Thr266.   
The visualization of the longer 45ns simulation and clustering of the pose 
for 45NsT indicates that ST_1_046 flips by 180° with exocyclic sulphur of 
rhodanine ring facing the base of P2 pocket (Figure8.3). This shifts the terminal 
phenyl and carboxylic group near P3 pocket, pyridine ring at P1 pocket while 3,4 
dimethoxy phenyl ring shifts towards C-terminal of the natural peptide. 
 ST_1_109 8.3.3.2
 
The pose predicted by the clustering of 25NsT shows that P2 pocket is 
occupied by terminal phenyl ring and rhodanine. However, the rhodanine ring 
was not found deep inside the P2 cavity. Pyridine ring was found close to P1 
pocket (Figure8.3).  The inward movement of α3 and outwards movement of α4  
loop resulted in bigger P2 pocket and smaller P3 pocket. Similar pose was 
observed from the clustering of longer 45NsT. 
 ST_1_R1N 8.3.3.3
 
The clustering of poses from 25NsT resulted in a single cluster indicating 
stability of predicted pose. The naphthalene ring was found to be parallel to P1  




Figure8.3  Orientation of ST_1_046, ST_1_109, ST_1_R1N, ST_1_261, ST_1_208 
25NsT and 45NsT belongs to 25ns and 45ns trajectory 




Figure8.4  Orientation of ST_1_202, ST_1_227, ST_1_159, ST_1_162, ST_1_222 and ST_1_227 
Pose1 and pose 2 belongs to cluster 1 and cluster 2, 25NsT and 45NsT belongs to 25ns and 45ns 
trajectory 
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pocket and forms π-alkyl interactions with Met231 and Lys234 (Figure8.3). The 
orientation of naphthalene ring causes rhodanine ring to move out of P2 pocket 
resulting in loss of interaction between exocyclic sulphur and phenyl ring of 
Phe254 in P2 pocket. 
 ST_1_208 8.3.3.4
 
The pose predicted as a result of clustering indicates that the ligand does 
not align along the MCL-1 binding grove but only interacts with the P2 pocket 
with N3 benzyl substituent (Figure8.3). However, longer simulation 45NsT 
indicates that ST_1_208 flips and N3 benzyl ring moves out of the pocket. 
 ST_1_247 8.3.3.5
 
Similar pose was predicted by clustering of 25NsT and 45NsT. As can be 
seen in that thiohydantoin ring and N3 benzyl substituent occupies P2 pocket 
(Figure8.4). In addition, naphthalene ring stays close to P1. The trajectory 
analysis of 45NsT reveals that ST_1_247 stays close to P2 pocket for complete 
45ns utilizing its more non-polar groups. 
 ST_1_202 8.3.3.6
 
As can be seen from Figure8.4 the thiohydantoin ring and N3 benzyl 
substituent occupies P2 pocket. However, the ligand was not found to be aligned 
with hydrophobic grove. Similar observation was found for longer 45NsT. 
 





The size of cluster_1 and cluster_2 was found to be almost similar in case 
of ST_1_159. In both poses, i.e. predicted by cluster_1 and cluster_2 (Figure8.4), 
its N3 benzyl substituent interacts with the pocket P2. 
 ST_1_249 8.3.3.8
 
The difference in the number of poses predicted for cluster_1 and 
cluster_2 of ST_1_249 is not large. Moreover, superimposition of the pose from 
45_NsT showed a third possible orientation for ligand. Analysis of three 
orientations revealed that, similar to pose predicted by cluster_1, ST_1_249 
utilizes its benzyl substituent to interact with the P2 pocket (Figure8.5). On 
inspection of 45NsT trajectory it was observed that after 20ns of simulation the 
compound starts flipping and after 40ns the carboxylic group faces P2 pocket. 
 ST_1_162 8.3.3.9
 
The predicted orientation indicates that ST_1_162 interacts with the P2 
pocket with its N3 benzyl substituent (Figure8.4). However, the pose predicted 
by 45NsT was found to be outside pocket P2.  On visualization of the 45NsT 
trajectory, it was observed that after initial stay in the pocket ST_1_162 moves 
out and is not able to interact with P2 pocket again. 
  




Figure8.5  Orientation of ST_1_249 and the distance between the pocket residues and closet atom 




Figure8.6  Comparison of the residues of α3 and α4 and loop α2-α4 loop for ST_1_046 25NsT, 
ST_1_046 45NsT, ST_1_109 25NsT and ST_1_R1N 25NsT  
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 ST_1_227 and ST_1_222 8.3.3.10
 
The pose predicted by clustering of 25NsT and 45NsT for both ST_1_227 
and ST_1_222 (Figure8.4) shows that its N3 benzyl substituent interacts with the 
pocket P2 while its biaryl ring attempts to interact with the P1 pocket. The 45NsT 
simulation of ST_1_227 and ST_1_222 reveals that thiazolidinedione ring is not 
able to enter P2 pocket and subsequently flips out of the pocket.        
 ST_1_261 8.3.3.11
 
The similar cluster size of best 3 clusters reveals that ST_1_261 was not 
able to form stable interactions. The pose predicted by cluster_1 (Figure8.3) 
indicates that N3 benzyl substituent occupies the P2 pocket of MCL-1. 
 Conformation of the residues 8.3.4
 
The conformations of residues were analyzed to understand the 
interactions and flexibility of α3 and α4 loop (Figure8.6). The conformations of 
receptor bound to active compounds i.e. ST_1_046, ST_1_R1N, ST_1_109 were 
analyzed. The residues at the α2-α3 and α3-α4 loop were found in different 
conformations. Among them, residues such as His224 and Asn223 seem to 
influence the P3 pocket. For ST_1_109, His224 shifts inside the pocket by 3.11Å 
thus shrinking the P3 pocket while not a significant change was observed for 
ST_1_R1N. The position of His224 was observed to be shifted slightly in 
opposite direction for 25NsT of ST_1_046. However, after a longer simulation, 
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the position of His224 was found close to the one observed in case of ST_1_109 
and ST_1_R1N.  
The position of Leu235 which is the last residue of α3 loop was found to 
be shifted by 3.9 Å for shorter ST_1_046 simulation. Val249 was found to shift 
outwards for all the poses except ST_1_R1N where it was found to move inside 
the cavity. Met231 was observed to possess three conformations i.e. facing 
towards α2-α3 loop, towards the P2 pocket and facing towards α3-α4 loop i.e. P1 
pocket. For both ST_1_109 and ST_1_R1N, Met231 was facing α3-α4 loop. For 
ST_1_R1N, it initially faces the α2-α3 loop but then shifts towards P2 pocket. 




The compounds with rhodanine ring, i.e. ST_1_046, ST_1_109 and 
ST_1_R1N, possess both endo and exocyclic sulphur. All three compounds form 
stable orientation by going deep into P2 pocket as well as by interacting with 
residues of other pockets. This can be correlated with better activity in 
comparison to compounds with different scaffold. The difference in ST_1_046 
and ST_1_109 lies in the position of methoxy group, i.e. ST_1_046 possess 3,4 
dimethoxy in comparison to 2,3 dimethoxy present in ST_1_109. As shown by 
poses predicted for ST_1_046, the methoxy group at meta position (meta-p) 
interacts with Val249 residue comprising P1 pocket, and either Leu246 or 
Lys234. Moreover, it was observed that the distance between the residues in 
proximity of the hydrogen atom present at metaposition is close to 4Å 
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(Figure8.5) which is not big enough for a bigger methoxy group attached to the 
ortho position. This results in ST_1_109 occupying P1 and P2 pocket while 
ST_1_046 occupies P1, P2 and P3 pockets. Similarly, ST_1_R1N due to large 
naphthalene ring was not able to align with the binding grove. 
The presence of endo and exocylic sulphur along with the exocyclic 
oxygen in ST_1_046 goes well with the electrostatics of the MCL-1 binding 
pocket. The binding grove of the MCL-1 is hydrophobic in nature which was 
utilized by the rhodanine ring while the electropositive surface interacted with the 
methoxy and carboxylic group flanking the rhodanine ring.  
With the increase in polar character of the central ring, interactions got 
weaker. Out of the endo and exocylic sulphur of rhodanine ring, exocyclic sulphur 
had major contribution as can be observed from the difference in activity of 
compounds with thiohydantoin and thiazolidinedione ring. 
 Thiohydantoin 8.3.5.2
 
The thiohydantoin ring, possess exocyclic sulphur while endocyclic 
sulphur is replaced by amino group. Exocyclic sulphur was able to interact with 
the residue occupying hydrophobic grove. However, due to increase in polar 
character, central ring was not able to align with the hydrophobic grove. This 
resulted in loss of key interactions leading to poor activity of ST_202, ST_208 
and ST_1_247.  
 





The hydantoin ring, possess endocyclic sulphur while exocyclic sulphur is 
replaced by oxygen. Due to presence of polar groups like endocyclic oxygen and 
carboxylic group in proximity, a strong interaction with the binding grove was not 




Thiazolidinedione ring lacks both endocyclic and exocyclic sulphur. The 
presence of polar groups hindered the alignment with hydrophobic grove of 
MCL-1. Thus, ST_159, ST_162 and ST_1_249 were not able to stay in 
hydrophobic grove for long duration resulting in least activity of compounds. In 
all four classes of compounds, presence of larger naphthalene ring did not 
improve the activity. The concluding remarks of this work have been described in 
Chapter 9. 






The last chapter summarizes the contributions (9.1) of this work towards 
the development of inhibitors against neuraminidase and MCL-1. Limitations and 
future work are described in 9.2 and Future work sections. 
 
 Contributions 9.1
In Chapter 2, 4 and 7, applications of computational methods like QSAR, 
docking and molecular dynamics was shown to develop drugs against diseases 
like influenza and cancer, i.e against neuraminidase and MCL-1.  
The data utilized to train the QSAR models was collected from a number 
of publications on different strains of neuraminidase and with different mutations. 
This made dataset quite diverse in terms of scaffold. In contrast, most of the 
previous studies have used a limited a number of compounds effective against a 
particular strain.  Dataset was processed and filtered thereby removing unwanted 
components. AD is a much desired property for any QSAR model to stop the 
prediction of the compounds not belonging to chemical space used to train the 
model. This ensured that prediction by the models in our work was accurate with 
low FPR and high accuracy. The base models had low FP and low false negative 
rate with Matthew’s correlation coefficient, denoting accuracy of the model, 
 CHAPTER 9: CONCLUSIONS                                                                         139 
 
 
greater than 95%. The consensus model, combining the strengths of top 10 base 
models, increased the accuracy of the model to 98% with low FPR of 0.8% and 
low FDR of 6.3%. The QSAR model developed in our work to screen PNI had 
better prediction accuracy than most of the previous models developed. This 
shows greater impact of our model in screening PNI. Moreover, it highlights the 
importance of diverse and clean dataset for building the model. This along with 
use of consensus modeling and AD can help to improve the prediction of the 
model considerably. It was observed that in comparison to overall accuracy, MCC 
dropped for validation set. Thus in future work, with such imbalanced dataset, 
MCC should be used as main criteria for evaluation.  In addition other modeling 
methods can also be implemented with diverse parameters can be used to build 
the base models. This will help to achieve the full potential of consensus model.  
As the aim of this work is to discover pan neuraminidase inhibitors, 
extensive docking study was performed to reduce the compounds obtained by 
screening of ZINC library to most potent compounds. None of the docking studies 
to my knowledge have used both neuraminidase group I and group II along with 
multiple strains for the discovery of neuraminidase inhibitors. The docking 
performed against group I and group II neuraminidase in open and closed form 
helped to cover two most important conformations of the neuraminidase. Various 
mutations have been reported in neuraminidase making it resistance against 
oseltamivir and zanamivir. Among the mutations reported, some have been found 
by reverse genetics while others are found in clinical samples. The viability of the 
viruses with mutations discovered by reverse genetics is yet not established. 
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Hence, the mutations established in clinical samples i.e. H274Y, N294S and 
R292K were selected for docking studies. These mutations also belong to 
different groups of neuraminidase with H274Y and N294S belonging to group I 
neuraminidase and R292K to group II neuraminidase. In addition, these mutations 
also cover resistance to all three recommended drugs against influenza i.e. 
oseltamivir, zanamivir and laninamivir. This ensured that the predicted inhibitors 
can act as pan neuraminidase inhibitors. Though this study uses three most 
important mutations, the probable inhibitors can be tested against other resistant 
strains to achiever real pan neuraminidase inhibitors.  
It was found that all top 5 compounds have similar orientation of the 
central ring, carboxylic, guanidino and acetamide group as compared to the 
existing inhibitors i.e. oseltamivir, zanamivir and laninamivir. The carboxylic 
group interacted with Arg118, Arg292, Tyr347 and Arg371 while guanidino 
group interacted with Glu119, Asp151, Trp178 and Glu227 and acetamide group 
interacted with Arg152. The side chain in compounds ZN88, ZN33 and ZN35 was 
bifurcated at 1st carbon providing it extra flexibility to negate the constriction in 
hydrophobic cavity. This flexibility allowed the side chain to be pushed 
backwards or rotate in H274Y and R292K mutation respectively. The shorter side 
chain was found to be facing the base of the cavity while the longer side chain 
was found close to the face of the cavity. Comparison of ZN33 and ZN35 indicate 
that maximum length of the side chain facing the base of cavity can be equal to 
propyl group. The longer side chain was found to be facing away from Glu276 
and closer to Ile222, Arg224, Ala246 (N1)/Ser246 (N9). Except N1_N294S, 
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ZN88 formed hydrogen bond between the amino group of side chain and Glu276, 
Glu277 and Asp151 in all systems. However, slight movement in Asp151 can 
lead to formation of hydrogen bond in N1_N294S. The guanidino group provided 
extra stability by binding to residues comprising 150 loop. Thus, it can be 
concluded that inhibitors with guanidino group, flexible side chain and amino 
group in side chain can act as pan neuraminidase inhibitors.  The low SD was 
observed for of ZN43, ZN88, ZN35 and ZN46 along with high average binding 
free energy. These compounds can be used to develop pharmacophore which later 
can used to develop potent pan neuraminidase inhibitors. Though this work 
covered most important conformations and resistant strains but these compounds 
can be tested against other resistant strains to check their validity as pan 
neuraminidase inhibitors. 
It is a long desired dream to develop drugs to cure cancer. Many drugs 
have been developed that target anti-apoptotic proteins like BCL-XL. However, 
these drugs fail due to overexpression of MCL-1 and the drugs ineffectiveness 
against MCL-1. The second phase of our work concentrated on deducing the 
cause behind the activity of drugs against MCL-1. Poses clustered from the 
multiple trajectories indicate that the P2 pocket is important for interaction.  
Though inhibitors against MCL-1 have been designed but most of them are not 
selective to MCL-1. Moreover, they compete with BH3-only peptides by binding 
to one or two pockets. Thus the binding cavity is not utilized fully. In our work, it 
was found that compounds spanning through majority of binding grove increases 
its activity.  
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The analysis of the orientation of different scaffolds reveals that non-polar 
nature of the rhodanine facilitates the occupancy of the hydrophobic grove. As the 
polar character of the ring increases, the interactions get weaker leading to poor 
activity. This caused the drop in activity of compounds with other scaffolds i.e. 
thiohydantoin, hydantoin and thiazolidinedione. ST_1_046 was found to span the 
hydrophobic grove thus occupying P1, P2 and P3 pockets. The alignment with the 
grove was assisted by the polar groups flanking the non-polar rhodanine ring. 
Hence, the electrostatics of the ligand can determine the interaction with the 
binding grove. It was also observed that as the ST_1_046 goes deeper into the 
hydrophobic grove resulting in better activity. However, not every pocket can 
accommodate larger ligands and it can be observed from the fact that larger 
naphthalene of ST_1_R1N caused a drop in activity.  
The analysis of residues reveals that α3 and α4 loop play important role in 
opening and closing of the pocket. The movement of α3 and α4 is due to greater 
flexibility of the loops linking them to adjacent helices. Val249 and Met231 seem 
to be crucial for the interaction and plasticity of the P2 pocket. Met231 by 
adopting different conformation can interact with inhibitors in both P1 and P2 
pocket. These findings can be expanded to design more potent and selective 
MCL-1 inhibitors. 
Five compounds had been synthesized by our collaborators, taking the 
computational results into consideration. Four compounds had a longer backbone 
with extension at N3 benzyl. In fifth compound i.e. ST_1_345, 3,4 dimethoxy is 
replaced by 3,4 diol. All five compounds had activity less than 20 µM while the 
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best compound had activity of about 13 µM. The compounds without extended 
structure had activity of about 15 µM. The extension of the structure did not 
improve activity. However, the central group can be made bulkier to occupy P2 
pocket to greater depth. This can further help to improve the activity. 
  




The limitation of any QSAR model is its dependence on the dataset. 
Though the model was trained on most elaborate dataset but the dataset could not 
be referred to as representative dataset of all the compounds. Inadequate 
representation of the compounds could affect the prediction accuracy.  
Docking was used to discover pan neuraminidase inhibitors. However, 
docking has limited accuracy in ranking the poses of the compounds. Energy 
minimization and pose rescoring was performed to overcome it but the error 
cannot be completely eliminated. There can be a chance of some important 
compound being overlooked in process of filtration. 
The docking against broad hydrophobic grove at surface of MCL-1 was 
quite challenging. Docking was not able to produce sufficient results to deduce 
the poses for inhibitors in order to establish a trend. Molecular dynamics was used 
to overcome those limitations and binding free energy was calculated. Though 
molecular dynamics was able to explain the results on basis of poses but binding 
free energy was not able to correlate with experimental binding activity.  
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 Future work 9.3
With time, the dataset used to train our neuraminidase QSAR model will 
no longer be sufficient. Thus, the QSAR model should be trained with new 
dataset for a better prediction. The QSAR model to predict inhibitors against 
influenza should be trained again with updated dataset including new inhibitors. 
The models can be tested using Akaike information criterion (AIC) which seems 
to be less prone to overfitting.  
The neuraminidase inhibitors predicted by our work could be analyzed by 
molecular dynamics study against important mutant strains. This will help to get 
more insights about the mutations and predict novel neuraminidase inhibitors. The 
compounds can be further verified by in-vivo and in-vitro studies to develop novel 
potent pan neuraminidase inhibitors. This model can be extended to other viral 
diseases facing resistance against existing inhibitors. In our present work non-
inhibitors were only used to build QSAR models and were not used in docking 
study. However, in future these compounds can be checked for possible role as 
neuraminidase inhibitor. Two probable inhibitors predicted in our study ZN33 and 
ZN35 come close to I222 and S246. Recently, it has been shown that both of 
these residues play role in resistance. Hence, in future more detailed study of can 
be performed involving mutations caused by I222 and S246. Compounds shown 
to be less effected by the mutant strains i.e. ZN43, ZN88, ZN35 and ZN46 will be 
used to develop pharmacophore model. This model will be used to develop novel 
and potent pan neuraminidase inhibitors. Recent discovered strains of 
neuraminidase i.e. N10 and N11 will be included for the screening and testing. 
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The effect of the compounds on the human sialidase will also be tested in the to 
check for any possible side effects. 
The results of MCL-1 indicate that inhibitors occupying a large surface of 
the hydrophobic grove can increase potency. However, occupancy of only three 
pockets, i.e. P1, P2 and P3, can lead to a potent inhibitor. The application the 
electrostatic properties of the ligand along with the selective nature of the pockets 
can be utilized to develop novel, potent and selective inhibitors against MCL-1. 
Inhibitors with bulkier non-polar central scaffold with electronegative ends can be 
developed. This approach can be extended to other members of BCL-2 protein 
family to develop selective inhibitors. Docking production for surface grove is 
poor. Hence, the algorithms should be trained to solve such hurdles. Also there is 
a need to establish a relation between number and duration of trajectories required 
for a molecular dynamics experiment, in order to attain a good correlation 
between predicted binding energy and experimental activity. Molecular dynamics 
will be performed to study the minimum duration and number of trajectories 
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